WO2001066551A2 - Azole compounds as therapeutic agents for fungal infections - Google Patents

Azole compounds as therapeutic agents for fungal infections Download PDF

Info

Publication number
WO2001066551A2
WO2001066551A2 PCT/IB2001/000300 IB0100300W WO0166551A2 WO 2001066551 A2 WO2001066551 A2 WO 2001066551A2 IB 0100300 W IB0100300 W IB 0100300W WO 0166551 A2 WO0166551 A2 WO 0166551A2
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
group
amino
compound
phenyl
Prior art date
Application number
PCT/IB2001/000300
Other languages
French (fr)
Other versions
WO2001066551A8 (en
WO2001066551A3 (en
Inventor
Ashwani Kumar Verma
Sudershan K. Arora
Jasbir Singh Arora
Ashok Rattan
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN198DE2000 external-priority patent/IN191188B/en
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Priority to AU34023/01A priority Critical patent/AU3402301A/en
Priority to JP2001565367A priority patent/JP2004501867A/en
Priority to EP01906061A priority patent/EP1278755A2/en
Priority to CA002402345A priority patent/CA2402345A1/en
Priority to NZ521241A priority patent/NZ521241A/en
Priority to PL01365072A priority patent/PL365072A1/en
Publication of WO2001066551A2 publication Critical patent/WO2001066551A2/en
Publication of WO2001066551A3 publication Critical patent/WO2001066551A3/en
Publication of WO2001066551A8 publication Critical patent/WO2001066551A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

  • the present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared to known compounds such as fluconazole and itraconazole and the processes for the preparation thereof.
  • This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing fungal infections in mammals, preferably humans.
  • AIDS AIDS or other physiologically or immunologically compromising syndromes
  • opportunistic fungal infections Most of these infections are caused by opportunistic pathogens, like species of Candida and Aspergillus and Cryptococcus neoformans.
  • pathogens like species of Candida and Aspergillus and Cryptococcus neoformans.
  • Candida species During the last 20 years, the incidence of sepsis fungal infection caused by Candida species has increased significantly in debilitated and immuno-compromised patients.
  • antineoplastic and immunosuppressive chemotherapies have also augmented fungal infections.
  • Cryptococcosis is a leading cause of morbidity among AIDS patients. The incidence of life threatening cryptococcal infection among these patients have been estimated to vary from 10 to 30%.
  • Aspergillus species is difficult to determine due to lack of accurate, reliable diagnostic methodologies and poor diagnosis.
  • the majority of Aspergillus infections in AIDS patients occur in late stage disease when immune cell functions are minimal. Impaired neutrophil and macrophage function is related to increased infection rates with Aspergillus species.
  • the most common species of Aspergillus causing disease in AIDS patients are A. fumigatus (83%), A. flavus (9%), A. niger (5%) and A. terreus (3%).
  • azole class Within the available drugs to treat fungal infections, the azole class appears to be most promising. This class of compounds inhibits the biosynthesis of ergosterol in fungi, which is the main constituent of fungal cell membrane. Of the various representative antifungals, early azoles used were miconazole, clotrimazole and tioconazole, which were potent against a wide range of fungi pathogenic to human. However, their in-vitro activity was not well exhibited in in- vivo models due to poor oral bioavailability and metabolic vulnerability.
  • Ketoconazole was the first drug that could be used against systemic fungal infection and successfully delivered through oral route. However, it was still quite susceptible to metabolic inactivation and also caused impotence and gynacomastia probably due to its activity against human cytochrome P450 enzymes.
  • Fluconazole is the current drug of choice for treatment of severe infections caused by Candida species and C. neoformans. However, fluconazole has only weak activity against isolates of Aspergillus species [minimum inhibitory concen ⁇
  • Itraconazole another triazole antifungal compound, generally is more active than fluconazole in the treatment of aspergillosis, but its activity in the clinic remains mixed as it showed variable oral availability, low solubility and caused ovarian cancer in animals. This may be due to its high protein binding properties.
  • the antifungals available in the market suffer with drawbacks such as, toxicity, narrow spectrum of activity and fungistatic profile rather fungicidal. Some of them also exhibit drug-drug interactions and, as a result, therapy becomes very complex.
  • demands for new antifungal agents with broad spectrum of activity and good pharmacokinetic properties has increased.
  • Voriconazole also shows non-linear pharmacokinetics besides some concern regarding its ocular toxicity, while ER 30346's anti-aspergillus activity, both in vitro and in vivo, is at best, only equal to itraconazole's activity.
  • SCH 56592 is a hydroxylated analogue of itraconazole with potent in-vitro and in-vivo activity, but is undetectable even when the serum drug concentration after several days of treatment are 25 to 100 times above the MIC for the most resistant C. neoformans.
  • the potent activity of SCH 56592 for C.neoformans is partially negated by its low concentration at the site of infection to the central nervous system.
  • the present invention relates to new substituted azole compounds which can be utilized to treat and/or prevent the fungal infections in mammals, preferably in humans.
  • the first aspect of the present invention provides compounds of Formula IA and its pharmaceutically acceptable salts, enantiomers, diastereomers, N- oxides, prodrugs or metabolites,
  • R is selected from the group consisting of (1 ) C- ⁇ -C alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C-i-C alkoxy and amino (2) C C 4 alkoxy, (3) halogen (4) formyl, (5) carboxyl (6) C-t-C acyloxy, (7) phenyl or substituted phenyl, (8) hydroxy, (9) nitro (10) amino
  • R-i and R 2 are each independently (1 ) hydrogen, (2) C 1 -C 4 alkyl group which is unsubstituted or substituted by 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C
  • Y is a phenyl group which is unsubstituted or substituted by substituents each independently selected from the group consisting of (1 ) halogen (2) nitro, (3) amino, (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy
  • R 3 is selected from the group consisting of C C alkyl group, halogen, hydroxy, C ⁇ -C alkoxy, nitro, amino, cyano, carboxyl and SO 2 R' wherein R' is hydrogen, alkyl or aryl; and
  • X-i, X 2 , Y ⁇ , Y 2 and Z are independently selected from the group consisting of halogen, nitro, cyano, amino, sulphonyl, aryl or substituted aryl, C ⁇ -C alkyl, C- ⁇ -C alkoxy, carboxyl or protected carboxyl.
  • Formula I A When R-i is other than hydrogen, Formula I A has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and S.S.
  • This invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR.
  • R is selected from the group consisting of hydrogen, C C 4 alkyl group which is unsubstituted or substituted, B is selected from oxygen and sulphur atoms;
  • R 5 is selected from the group, (1 ) hydrogen, (2) C C 4 alkyl group which is unsubstituted or substituted by 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C- ⁇ -C alkoxy and amino (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C 1 -C 4 alkyl which is unsubstituted or substituted with 1-3 substituted each independently selected from the group consisting of halogen, hydroxy, C-i- C 4 alkoxy and amino (b) C C 4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) C ⁇ -C 4 alkoxy (g) C C 4 alkoxycarboxyl amino (h) phenyl or naphthyl oxycarbonyl amino (i) semicarbazido (j) formamido (k) thioformamide (I) hydroxy (m)
  • Formula IA When Ri is other than hydrogen, Formula IA has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and SS. This invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR.
  • Formula II When Ri is other than hydrogen, Formula II has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and SS.
  • This invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR.
  • the fourth aspect of the present invention provides compounds of Formula III and its pharmaceutically acceptable salts, enantiomers, diastereomers, N- oxides, prodrugs or metabolites,
  • Formula III When Ri is other than hydrogen, Formula III has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and SS. This invention relates to the mixture of enantiomers as well as individual isomers and the most preferred in this situation is RR.
  • Pharmaceutically acceptable, non-toxic, acid addition salts of the compounds of the present invention of Formulae IA, 1 B, II and 111 may be formed with inorganic or organic acids, by methods well known in the art.
  • compositions containing the novel compounds of the present invention in the treatment of fungal infections.
  • the present invention also includes within its scope prodrugs of the compounds of Formulae IA, IB, II and III.
  • prodrugs will be functional derivatives of these compounds which readily get converted in vivo into defined compounds.
  • Conventional procedures for the selection and preparation of suitable prodrugs are known.
  • the invention also includes pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, prodrugs, metabolites of the above formulae in combination with pharmaceutically acceptable carriers and optional excipients.
  • R is selected from the group consisting of (1 ) C ⁇ -C 4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C-i-C 4 alkoxy and amino (2) C 1 -C 4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C 1 -C 4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl, R-i and R 2 are each independently selected from the group consisting of (1 ) hydrogen, (2) C 1 -C 4 alkyl group
  • R 3 is selected from the group consisting of C- 1 -C 4 alkyl group, halogen, hydroxy, C 1 -C 4 alkoxy, nitro, amino, cyano, carboxyl and SO 2 R' wherein R' is hydrogen, alkyl or aryl; and
  • X ⁇ , X 2 , Y 1 , Y 2 and Z are independently selected from the group consisting of halogen, nitro, cyano, amino, sulphonyl, aryl or substituted aryl C 1 -C 4 alkyl, C 1 -C 4 alkoxy, carboxyl or protected carboxyl.
  • Formula I when Ri is other than hydrogen, Formula I has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and SS, this invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR, which comprises reacting 1-[2- (2,4-disubstituted phenyl)-2,3-epoxy derivative of 1 ,2,4-triazole of Formula IV, wherein X, R and R 1 f are the same as defined above, with triazol-3-one derivatives of Formula V, wherein R 2 ,, R 3 , Xi, X 2 , Y, Y ⁇ , Y2 and Z have the same meanings, as defined above, in the presence of sodium hydride to afford the desired compound of Formula I A, wherein X, X1 2, Y-i, Y2. Z, R, R-i, R 2 and R 3 have the same meanings as defined above.
  • substituents selected from (a) Ci - C 5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C 1 -C 4 alkoxy and amino, (b) halogen (c) (C ⁇ -C 4 alkyl) halo, (d) C ⁇ -C 4 alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetrafluoropropyl and
  • this invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR, which comprises reacting epoxide derivative of Formula VI, wherein X, R, R 1 ( R 2 , R 3 , X-i, X 2 , Y, Y-i, Y2 and Z are the same as defined above with 1 ,2,4-triazole to afford a compound of Formula IA.
  • FORMULA H There is provided a process for preparing a compound of Formula II, wherein X, R, R-i, R 4 , R 5 , Y and B have the same meanings as defined earlier, also when Ri is other than hydrogen, Formula II has two asymmetric centres and there are four possible enantiomers i.e.
  • This compound of Formula XII is further reacted with 1 ,2,4-triazole to obtain 2- (1 H-1 ,2,4-triazol-1-yl)-2'-4'-difluoroacetophenone of Formula XIII.
  • TMSI trimethyl sulphoxonium iodide
  • X ⁇ > X2, Y1 , Y2 and Z are the same as defined earlier, are prepared by reacting substituted phenyl piperazine of Formula XIV, wherein X 1 f X 2 , Y ⁇ , Y 2 and Z are the same as defined earlier, is reacted with 4-chloronitrobenzene to give the corresponding nitroaryl compound of Formula XV, which on catalytic reduction affords the anilino derivative of Formula XVI.
  • the compound of Formula XVI is acylated with phenyl chloroformate to afford phenyl carbamate derivatives of Formula XVII.
  • TMSI trimethylsulphoxonium iodide
  • reaction temperature and duration of the reaction may be used.
  • Schemes IA, IB to IX include:
  • Step 1 Preparation of 2-chloro-2', 4'-difluoro acetophenone.
  • Step -1 The product obtained in Step -1 was reacted with 1 ,2,4-triazole (1.2 molar equivalent) in the presence of sodium bicarbonate as base and toluene as solvent under refluxing condition. After the reaction was over, the reaction mixture was poured into crushed ice and extracted with toluene. The combined organic layer was then washed with water and concentrated under reduced pressure to give brown semisolid compound which was recrystallized from ethyl acetate - hexane mixture to give light yellow solid compound which was then used as such in the next step.
  • 1 ,2,4-triazole 1.2 molar equivalent
  • Step 3 Preparation of 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1 H-1 ,2,4- triazole
  • Step 2 product was dissolved in toluene, followed by the addition of trimethylsulfoxonium iodide (TMSI), cetramide and 20% aq. sodium hydroxide solution. This mixture was then heated at 60° C for 4 hrs. After the reaction was over, it was diluted with toluene and poured into chilled water. The organic layer was washed with water and concentrated under reduced pressure to give light brown oil which was used after column chromatographic purification (silica gel) in the next step.
  • TMSI trimethylsulfoxonium iodide
  • cetramide 20% aq. sodium hydroxide solution
  • Step 4 Preparation of 1 -(substituted phenyl)-4-(4-nitrophenyl) piperazine.
  • Step 5 Preparation of 1 -(substituted phenyl)-4-(4-aminophenyl)piperazine
  • Method 1 The compound of Step 4 was dissolved in methanol and Palladium on charcoal (wet, 10% w/w) was added under nitrogen followed by the addition of ammonium formate (5 molar equivalent). The reaction mixture was
  • Step 4 The compound of Step 4 was refluxed in ethyl acetate in the presence of 5.0 molar equivalent stannous chloride dihydrate for 6-8 hrs. After completion of the reaction, the reaction mixture was poured into 10% aq. sodium bicarbonate and extracted with ethyl acetate. The combined organic layer was then washed with water dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the desired product.
  • Step 6 Preparation of [4-(4-(substituted/unsubstituted phenyl) -1 -piperazinyl] phenyl carbamate
  • the amine obtained from Step 5 was dissolved in a mixture of dichloroethane (DCE) and pyridine and cooled to 5°C. A solution of phenylchloroformate (1.4 molar equivalent) in DCE was added into the solution of
  • reaction mixture was stirred at 25-30°C for 3-5 hours. Solvent was evaporated off under reduced pressure to give brownish residue which on triturating with n-hexane gave brown solid. It was then obtained was washed with 5% aq. solution of sodium bicarbonate and water. It was then dried under
  • Step 7 Preparation of N-[4-[(4-substituted phenyl) 1-piperazinyl]phenyl]hydrazine carboxamide.
  • Step 8 4-(4-Substituted phenyl)-1-piperazin]phenyl-3H-1 ,2,4-triazol-3-ones.
  • Step 9 Preparation of 2-[(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)- propyl]-4-[4-[4-substitutedphenyl-1-piperazinyl]phenyl]-3-(2H,4H)-1 ,2,3- substituted triazol-4-one.
  • reaction mixture was cooled to 35-40°C, poured it into chilled water (50 ml) and extracted with ethyl acetate (3x 100ml). The combined organic layer was washed with water (4x50ml), dried over anhydrous sodium sulphate and concentrated under vacuum to give an oily residue (0.3 gm). The oil was purified by column chromatography (silica gel 100-200 mesh) using hexane-ethyl acetate (1 :1 ) followed by ethyl acetate or by crystallisation from suitable solvent to give the required compound.
  • Step 1 Preparation of 2-chloro-2-methyl-2',4'-difluoro acetophenone
  • reaction mixture was stirred at room temperature for 5-7 hours.
  • reaction mixture was diluted with DCE and poured into chilled aq. hydrochloric acid solution (5%). The mixture was extracted with DCE and the combined organic layer was washed with 5% aq. sodium bicarbonate solution and water. The solvent was evaporated off under reduced pressure to afford an oil.
  • Step 2 Preparation of 2- ⁇ [4-[4-[4-(substituted/unsubstituted phenyl)piperazin- yl]phenyl-(2H,4H)-1 ,2,4-triazol-3-one-2-yl] ⁇ -2(R/S)-methyl-2',4'- difluoroacetophenone
  • reaction mixture was cooled to 25-30°C, poured into chilled water and extracted with ethyl acetate. The combined organic layer was washed with water, dried over anhydrous sodium sulphate and concentrated to give an oily residue under vacuum.
  • the crude product was purified by column chromatography (silica gel 100-200 mesh) using hexane-ethyl acetate (1 :1) followed by using ethyl acetate to give the required compound.
  • Step 3 Preparation of 2- ⁇ [1 (R/S)-methyl-2-(2',4'-difluorophenyl)-2,3-epoxy- propyl]-4-[4-(substituted phenyl)piperazinyl]phenyl] ⁇ -3-(2H,4H)-1 ,2,4-substituted thiazolone.
  • TMSI trimethylsulfoxonium iodide
  • Step 4 Preparation of 2- ⁇ [1 R,2R/1S,2S/1 R,2S/1S,2R]2-[(2,4-Difluoro phenyl)-2- hydroxy-3-methyl-3-(1 -H-1 ,2,4-triazoM -yl)propyl] ⁇ -4- ⁇ 4-[4- (substituted/unsubstituted phenyl)-1-piperazinyl]phenyl] ⁇ -3-(2H,4H)-1 ,2,3- substituted triazol-4-one].
  • the nitro compound (18.0g) was refluxed in ethyl acetate (150ml) in the presence of stannous chloride dihydrate (55.5g) for 8 hours. After completion of the reaction, the reaction mixture was poured into 10% aqueous sodium bicarbonate (500ml) and extracted with ethyl acetate (3 x 150ml). The combined organic layer was washed with water (3 x 100ml) and then dried over anhydrous sodium sulfate. The organic layer was concentrated under vacuum to give the desired amine (15.3g, brown oil; yield:93%).
  • reaction mixture was cooled to about 15°C.
  • a solution of phenylchloroformate (11.67g) in DCE (10ml) was added into the solution of amine at such a rate that reaction temperature remained below 20°C.
  • reaction mixture was stirred at 25-30°C for about 3 hours.
  • Solvent was evaporated off under reduced pressure to give brownish residue which on triturating with n-hexane (150ml) gave brown solid. Solid was washed with n-hexane (2x100ml), 5% aq.
  • Step 1 Preparation of 2- ⁇ 4-[4-[4-(2-methyl-5-chlorophenyl)piperazinyl]phenyl ⁇ - (2H,4H)-1 ,2,4-triazol-3-one-2-yl ⁇ -2(R/S)-methyl-2,4-difluoroacetophenone.
  • Step 2 Preparation of 2-[1-(R/S)-methyl-2-(2'-4'-difluorophenyl)-2,3-epoxy- propyl]-4- ⁇ 4-[4-(5-chloro-2-methylphenyl)piperazinyl]phenyl] ⁇ -3-(2H,4H)-1 ,2,4- triazolone.
  • Step 3 2- ⁇ [1 R2R/1 S2S]-2-(2,4-Difluoropheny!)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazoM -yl) propyl ⁇ -4- ⁇ 4-[4-(5-chloro-2-methylphenyl)-1 -piperazinyl]phenyl ⁇ -3- (2H,4H)-1 ,2,4-triazolone (Compound No. 21 )
  • reaction mixture was cooled to 25-30°C, poured into chilled brine (70.0ml) and extracted with ethyl acetate (3 x 75ml). The combined organic layer was washed with water (2x250ml), dried over sodium sulfate and concentrated under vacuum to give an oil.
  • Compound obtained actually was a mixture of two pairs of diastereomers showing two spots on TLC (Ethyl acetate).
  • Step 1 Preparation of 3-[N-methyl-N-(4-nitrophenyl)]-2-(2,4-difluorophenyl)-1- (1 H-1 ,2,4-triazolyl)- propan-3-amino-2-ol.
  • Step 2 Preparation of 3-[N-methyl-N-(4-aminophenyl)]-2-(2,4-difluorophenyl)-1- (1 H-1 ,2,4-triazolyl)- propane-3-amino-2-ol.
  • Step 3 Preparation of 3-[4-(4-Chlorophenylthioureido)N-methyl-N-phenyl]-2-(2,4- difluorophenyl)-1-(1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 89)
  • Step 1 Preparation of 2- ⁇ 4-[4-acetyl-1 -piperazinyl]-phenyl]-2(R/S)-methyl-2,4- difluoroacetophenone
  • Step 2 Preparation of 1-(R/S)-methyl-2,3-epoxypropyl-2- ⁇ 4-[(4- acetylpiperazinyl)] phenoxy ⁇ -2-(2',4'- difluorobenzene)
  • Step 3 Preparation of 1- ⁇ 4-[4-Acetylpiperazinyl)-phenyl]-2-(2,4-difluorophenyl)- 1 (R/S)- methyl-3-(1 H-1 ,2,4- triazolyl)-propane-2-ol)]
  • Step 2 product (7.0 g) in
  • Step 4 Preparation of 1-[4-(4-(piperazinyl)phenoxy]-2-(2,4-difluorophenyl)-
  • Step 3 product (6.0 g) was dissolved in 1 ,4-dioxane (50 ml) followed by the addition of a solution of sodium hydroxide (1.0 g) in water (50 ml). Heated the reaction mixture to reflux, stirred it at reflux for about 5 hrs and concentrated under reduced pressure to give a brown semi-solid residue. This brown semi solid was redissolved in ethyl acetate (200 ml), washed with DM water (2x100 ml), dried over sodium sulphate and concentrated to get a pure brown semi-solid (4.5 g; 81 %).
  • Step 5 Preparation of [1 R2R/1S2S) 1- ⁇ 4-[4-(4-chlorophenylureido)-piperaziny]- phenoxy ⁇ -2-(2,4- difluorophenyl)-1 -methyl-3-(1 H-1 ,2,4-triazolyl)-propan-2-ol. (Compound No. 77) and
  • Step 4 product (Formula VII) (800 mg) in anhydrous acetonitrile (5 ml) followed by the addition of p-chlorophenyl isocyanate (3.44 mg).
  • the reaction mixture so obtained was stirred for 1 hour at room temperature and after the reaction was over, the solvent was evaporated off to give brown semi solid residue which was purified using column chromatography.
  • the two spots observed on TLC were separated by preparative HPLC (Upper spot, 50mg, 30%, compound No. 77; Lower spot, 25mg, 20%, Compound No. 78)
  • Compounds of the Formulae IA, IB, II and III as shown herein, and their salts are useful in the curative or prophylactic treatment of fungal infections in animals, including humans.
  • they are useful in treating topical fungal infection in man caused by, among other organisms, species of Candida, Trichophyton, Microsporum or Epidermophyton in mucosal infections caused by C. albicans (e.g., thrush and vaginal candidiasis).
  • C. albicans e.g., thrush and vaginal candidiasis
  • They can also be used in the treatment of systemic fungal infections caused by, for example, species of Candida (e.g., Candida albicans), Cryptococcus neoformans or Aspergillus fumigatus.
  • the compounds of the present invention have been found to have unexpectedly good activity against clinically important Aspergillus species fungi.
  • the in vitro evaluation of the antifungal activity of the compounds can be performed by determining the minimum inhibitory concentration (MIC) which is the concentration of the test compound in Rosewell Park Memorial Institute (RPMI) 1640 liquid medium buffered with (3-[Morpholino]propanesulphonic acid) MOPS to pH7. at which there is significant inhibition of the particular fungi
  • MIC minimum inhibitory concentration
  • RPMI Rosewell Park Memorial Institute
  • M27A document for Candida and Cryptococcus and M38P for Aspergillus was used to determine the MIC against yeast and filamentous fungi with suitable modifications for dermatophytes. Two quality control strains were included each time the MIC were determined and readings recorded only when the QC results fell into the
  • the in vivo evaluation of the compound can be carried out at a series of dose levels by oral or I.V. injection to mice which are inoculated I.V. with the minimum lethal dose of Candida albicans, Cryptococcus neoformans or Aspergillus fumigatus by the tail vein.
  • Activity is based on the survival of a treated group of mice after the death of an untreated group of mice.
  • Aspergillus and Cryptococcus infections target organs were cultured after treatment to document the number of mice cured of the infection for further assessment of activity.
  • the antifungal compounds of the formula and their salts can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • they can be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents.
  • They can be injected parenterally, for example, intravenously, intramuscularly or subcutaneously.
  • parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
  • solubility of a compound of the Formulae IA, IB, II and III in an aqueous medium may be improved by complexation with a hydroxyalkyl derivative of a cyclodextrin in the preparation of an appropriate pharmaceutical composition.
  • the daily dosage level of the antifungal compounds of the Formulae IA, IB, II and III and their salts will be from 0.01 to 20 mg/kg (in single or divided doses) when administered by either the oral or parenteral routes.
  • tablets or capsules of the compound will contain from 5 mg to 0.5 gm of active compound for administration one, two or more at a time, as appropriate.
  • the physician in any event will determine the actual dosage which will be most suitable for an individual patient and it will vary with age, weight and response of the particular patient.
  • the above dosages are exemplary of the average case, there can, of course, be individual instances, where higher or lower dosage ranges are required and such are within the scope of this invention.
  • the antifungal compound or Formulae IA, IB, II and III can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder.
  • they can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin, or they can be incorporated, at a concentration between 1 and 10 % into an ointment consisting of a white wax or white soft paraffin base together with such stabilizers and preservatives as may be required.
  • Cryptococcosis is a leading cause of morbidity and mortality among AIDS patients. In many patients Cryptococcosis is the first indication of AIDS. The incidences of life-threatening cryptococcal infection among patients with AIDS has been estimated to vary from 10 - 30 %. During initial therapy, 10 - 20 % of these patients die and 30 - 60 % patients succumb within 12 months (Powderly WG: Cryptococcus meningitis and AIDS Clin. Infect. Dis. 1993; 17: 837 - 842).
  • Amphotericin B has changed disseminated cryptococcosis from uniformly fatal infection to curable infection, but since Amphotericin B penetrates the central nervous system poorly, intraventricular injection may have to be administered for successful management of severe cases of Cryptococcal meningitis. Fluconazole has excellent pharmacokinetics in CSF and performs equally well in patients with Cryptococcal meningitis.
  • Invasive aspergillosis has become a leading cause of death, mainly among patients suffering from acute leukaemia or after allogenic bone marrow transfusion and after cytotoxic treatment of these conditions. It also occurs in patients with conditions such as AIDS and chronic granulomatous disease. At present, only Amphotericin B and Itraconazole are available for treatment of aspergillosis. In spite of their activity in vitro, the effect of these drugs in vivo against Aspergillus fumigatus remains low and as a consequence mortality from invasive aspergillosis remains high.
  • Candida Histoplasma capsulatum, Cryptococcus neoformans, dermatophytes, Aspergillus fumigatus and A. flavus.
  • the action on many of these strains, especially against Cryptococcus and Aspergillus is fungicidal in vitro.
  • Compounds of this invention have enhanced antifungal activity against the important fungal pathogens of men and animals.
  • a single oral dose of 12.5 mg / kg bw. (0.25 mg per mouse) is adequate to offer significant protection to mice infected via the tail vein by lethal dose of C. albicans A-26.
  • the compounds of this invention cross the blood brain barrier to excert their potent anti cryptococcal activity in the brain.
  • lethal infection (1 million cells of C. neoformans) were injected into the cranium of the animal, oral dosing with 25 mg/kg bw. BID for 8 days reduced the count by 4 logs, causing 99.99 % reduction in the fungal load.

Abstract

The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared to known compounds such as fluconazole and itraconazole and the processes for the preparation thereof. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing fungal infections in mammals, preferably humans.

Description

AZOLE COMPOUNDS AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS
Field of the Invention
The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared to known compounds such as fluconazole and itraconazole and the processes for the preparation thereof. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing fungal infections in mammals, preferably humans.
Background of the Invention
Life-threatening, systemic fungal infections continue to be a significant problem in health care today. In particular, patients who become "immuno- compromised: as a result of diabetes, cancer, prolonged steroid therapy, organ transplantation antirejection therapy, the acquired immune deficiency syndrome
(AIDS) or other physiologically or immunologically compromising syndromes, are especially susceptible to opportunistic fungal infections. Most of these infections are caused by opportunistic pathogens, like species of Candida and Aspergillus and Cryptococcus neoformans. During the last 20 years, the incidence of sepsis fungal infection caused by Candida species has increased significantly in debilitated and immuno-compromised patients. In addition, the more aggressive and frequently used broad spectrum antibiotic, antineoplastic and immunosuppressive chemotherapies have also augmented fungal infections. Cryptococcosis is a leading cause of morbidity among AIDS patients. The incidence of life threatening cryptococcal infection among these patients have been estimated to vary from 10 to 30%. During initial therapy, 10 to 20% of these patients die and 30 to 60% patients succumb within a year. Amphoteracin B has changed disseminated cryptococcosis from uniformly fatal infection to curable infection but since Amphoteracin B penetrates the central nervous system poorly, interventricular injection may have to be administered for successful management of severe cases of patients with cryptococcal meningitis. Invasive aspergilfosis has also become a leading cause of death, mainly among patients suffering from acute leukaemia or after allogenic bone marrow transfusion and after cytotoxic treatment of these conditions. It also occurs in patients with condition such as AIDS and chronic granulomatous disease. At present, only Amphoteracin B and itraconazole are available for treatment of aspergillosis. Inspite of their activity in-vitro, the effect of these drugs in-vivo against Aspergillus fumigatus remains low and as a consequence mortality from invasive aspergillosis remains high.
In addition, the emergence of fluconazole -resistant isolates of pathogenic yeasts, particularly in HIV-positive patients, and the general nature of treating fungal infections caused by Aspergillus species, are of growing concerns among infections disease specialists. The precise incidence of infections caused by
Aspergillus species is difficult to determine due to lack of accurate, reliable diagnostic methodologies and poor diagnosis. The majority of Aspergillus infections in AIDS patients occur in late stage disease when immune cell functions are minimal. Impaired neutrophil and macrophage function is related to increased infection rates with Aspergillus species. The most common species of Aspergillus causing disease in AIDS patients are A. fumigatus (83%), A. flavus (9%), A. niger (5%) and A. terreus (3%).
Within the available drugs to treat fungal infections, the azole class appears to be most promising. This class of compounds inhibits the biosynthesis of ergosterol in fungi, which is the main constituent of fungal cell membrane. Of the various representative antifungals, early azoles used were miconazole, clotrimazole and tioconazole, which were potent against a wide range of fungi pathogenic to human. However, their in-vitro activity was not well exhibited in in- vivo models due to poor oral bioavailability and metabolic vulnerability.
Ketoconazole was the first drug that could be used against systemic fungal infection and successfully delivered through oral route. However, it was still quite susceptible to metabolic inactivation and also caused impotence and gynacomastia probably due to its activity against human cytochrome P450 enzymes.
Fluconazole is the current drug of choice for treatment of severe infections caused by Candida species and C. neoformans. However, fluconazole has only weak activity against isolates of Aspergillus species [minimum inhibitory concen¬
tration (MIC) values of 400 μg/ml], since the drug has low potency (IC50 = 4.8 μM)
against lanosterol 14α - demethylase, the target enzyme in the fungus.
Itraconazole, another triazole antifungal compound, generally is more active than fluconazole in the treatment of aspergillosis, but its activity in the clinic remains mixed as it showed variable oral availability, low solubility and caused ovarian cancer in animals. This may be due to its high protein binding properties. Thus, the antifungals available in the market suffer with drawbacks such as, toxicity, narrow spectrum of activity and fungistatic profile rather fungicidal. Some of them also exhibit drug-drug interactions and, as a result, therapy becomes very complex. In view of the high incidence of fungal infections in immunocompromised patients and the recent trends for the steady increase of the populations of such patients, demands for new antifungal agents with broad spectrum of activity and good pharmacokinetic properties has increased. Thus, the continuing demand for safe and effective broad spectrum antifungal agent with favourable pharmacokinetic properties has spurred both the design and development of new systemically active antifungal triazoles. The development of earlier compounds which were referred to as second generation triazoles and which included SCH 39304 (Genaconazole), SCH42427 (Saperaconazole) and BAY R 8783 (Electrazole) had to be discontinued as a result of safety concerns. Another promising second generation triazole, D0870, a derivative of fluconazole, exhibited significant variations in plasma pharmacokinetics besides having weak antiaspergillus activity. Other fluconazole derivatives in different stages of development include voriconazole and ER 30346 (BMS 207147). Voriconazole also shows non-linear pharmacokinetics besides some concern regarding its ocular toxicity, while ER 30346's anti-aspergillus activity, both in vitro and in vivo, is at best, only equal to itraconazole's activity. SCH 56592, is a hydroxylated analogue of itraconazole with potent in-vitro and in-vivo activity, but is undetectable even when the serum drug concentration after several days of treatment are 25 to 100 times above the MIC for the most resistant C. neoformans. Thus, the potent activity of SCH 56592 for C.neoformans is partially negated by its low concentration at the site of infection to the central nervous system. The above azole candidates are discussed in the following publications: SCH 56592; Antimicrob. Agents Chemother. 40, 1910 (1996); 36th Interscience conference Antimicrob Agents Chemother, September, 1996, New Orleans, Abst. F87-F102; TAK-187; 36th Interscience conference Antimicrob Agents Chemother, September, 1996, New Orleans, Abst. F74; EP 567892; ER-30346: Drugs of the
Future, 21, 20 (1996).
Various compounds having thiol, sulphone, sulphonamides, Λ/-di- substituted sulphonamides, triazoles and tetrazoles of the second asymmetric centre of fluconazole with various side chains have been covered in U.S. Patent Nos. 5,466,820; 5,371 ,181 and 5,371 ,101 assigned to Takeda. But none of them satisfies the above-described medical needs completely, either being weak in spectrum, potency, safety or having undesired pharmacokinetics.
Despite the therapeutic success of fluconazole and itraconazole, there remains a significant need for improved, broad spectrum, better tolerated, less toxic, more potent antifungal compounds with minimal potential for development of resistance among target fungi.
SUMMARY OF THE INVENTION
The present invention relates to new substituted azole compounds which can be utilized to treat and/or prevent the fungal infections in mammals, preferably in humans. The first aspect of the present invention provides compounds of Formula IA and its pharmaceutically acceptable salts, enantiomers, diastereomers, N- oxides, prodrugs or metabolites,
Figure imgf000007_0001
FORMULA IA
wherein X is selected from the group consisting of CH2, CO, CS, SO2 and -N=N-;
R is selected from the group consisting of (1 ) C-ι-C alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C-i-C alkoxy and amino (2) C C4 alkoxy, (3) halogen (4) formyl, (5) carboxyl (6) C-t-C acyloxy, (7) phenyl or substituted phenyl, (8) hydroxy, (9) nitro (10) amino
(11 ) furyl, (12) triazolyl, (13) thienyl, (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
R-i and R2 are each independently (1 ) hydrogen, (2) C1-C4 alkyl group which is unsubstituted or substituted by 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C
C4 alkoxy and amino; (3) nitro, (4) amino (5) cyano, (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is alkyl or aryl and (8) CrC alkoxy;
Y is a phenyl group which is unsubstituted or substituted by substituents each independently selected from the group consisting of (1 ) halogen (2) nitro, (3) amino, (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy
(7) Cι-C alkoxy and (8) SO2R' wherein R' is hydrogen alkyl or aryl;
R3 is selected from the group consisting of C C alkyl group, halogen, hydroxy, Cι-C alkoxy, nitro, amino, cyano, carboxyl and SO2R' wherein R' is hydrogen, alkyl or aryl; and
X-i, X2, Yι, Y2 and Z are independently selected from the group consisting of halogen, nitro, cyano, amino, sulphonyl, aryl or substituted aryl, Cι-C alkyl, C-ι-C alkoxy, carboxyl or protected carboxyl.
When R-i is other than hydrogen, Formula I A has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and S.S. This invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR.
According to the second aspect of the present invention, there are provided compounds of Formula IB, and its pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, prodrugs or metabolites,
Figure imgf000008_0001
wherein X, R, Ri, R2, Y and R3 are the same as defined earlier,
R is selected from the group consisting of hydrogen, C C4 alkyl group which is unsubstituted or substituted, B is selected from oxygen and sulphur atoms; and
R5 is selected from the group, (1 ) hydrogen, (2) C C4 alkyl group which is unsubstituted or substituted by 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C-ι-C alkoxy and amino (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C1-C4 alkyl which is unsubstituted or substituted with 1-3 substituted each independently selected from the group consisting of halogen, hydroxy, C-i- C4 alkoxy and amino (b) C C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) Cι-C4 alkoxy (g) C C4 alkoxycarboxyl amino (h) phenyl or naphthyl oxycarbonyl amino (i) semicarbazido (j) formamido (k) thioformamide (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF3 and (u) OCF3 (4) naphthyl or naphthyl (Cι-C alkyl) which may be substituted with 1-6 substituents selected from (a) C-1-C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C C4 alkoxy and amino (b) halogen, (c) (Cι-C4 alkyl) halo (d) C C4 alkoxy (e) hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetrafluoropropyl and (m) tetrafluoropropoxyl.
When Ri is other than hydrogen, Formula IA has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and SS. This invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR.
According to the third aspect of the present invention there are provided compounds of Formula II and its pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, prodrugs or metabolites,
Figure imgf000010_0001
FORMULA H
wherein X, R, R ( R4l R5, B and Y have the same meanings as defined earlier.
When Ri is other than hydrogen, Formula II has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and SS. This invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR. The fourth aspect of the present invention provides compounds of Formula III and its pharmaceutically acceptable salts, enantiomers, diastereomers, N- oxides, prodrugs or metabolites,
Figure imgf000011_0001
FORMULA IH
wherein X, R, Ri, Y, B and R5 have the same meanings as defined above.
When Ri is other than hydrogen, Formula III has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and SS. This invention relates to the mixture of enantiomers as well as individual isomers and the most preferred in this situation is RR.
Pharmaceutically acceptable, non-toxic, acid addition salts of the compounds of the present invention of Formulae IA, 1 B, II and 111 may be formed with inorganic or organic acids, by methods well known in the art.
It is further object of the invention to provide compositions containing the novel compounds of the present invention in the treatment of fungal infections.
The present invention also includes within its scope prodrugs of the compounds of Formulae IA, IB, II and III. In general, such prodrugs will be functional derivatives of these compounds which readily get converted in vivo into defined compounds. Conventional procedures for the selection and preparation of suitable prodrugs are known.
The invention also includes pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, prodrugs, metabolites of the above formulae in combination with pharmaceutically acceptable carriers and optional excipients.
Other advantages of the invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by the practice of the invention.
DETAILED DESCRIPTION OF THE INVENTION
In order to achieve the above mentioned aspects and in accordance with the purpose of the invention as embodied and described herein, there are provided processes for the syntheses of compounds of Formulae IA,1 B, II and III, wherein R, Ri, R2, R3, R4, R5X, Y, X1, Yι, , X2 N2 , Z and B are the same as defined earlier. The compounds of Formulae IA.1 B, II and III of the present invention may be prepared by following the reaction sequences as depicted below in schemes IA, IB to IX.
SCHEME IN
Figure imgf000013_0001
FORMULA V
Figure imgf000013_0002
Figure imgf000013_0003
FORMULA IA
In Scheme IA there is provided a process for preparing a compound of Formula IA, as shown above, wherein
X is selected from the group consisting CH2, CO, CS, SO2 and -Ν=Ν-, R is selected from the group consisting of (1 ) Cι-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C-i-C4 alkoxy and amino (2) C1-C4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C1-C4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl, R-i and R2 are each independently selected from the group consisting of (1 ) hydrogen, (2) C1-C4 alkyl group which is unsubstituted or substituted by 1- 3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) C1-C4 alkoxy, Y is a phenyl group which is unsubstituted or substituted by substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) C1-C4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl,
R3 is selected from the group consisting of C-1-C4 alkyl group, halogen, hydroxy, C1-C4 alkoxy, nitro, amino, cyano, carboxyl and SO2R' wherein R' is hydrogen, alkyl or aryl; and
Xι, X2, Y1, Y2 and Z are independently selected from the group consisting of halogen, nitro, cyano, amino, sulphonyl, aryl or substituted aryl C1-C4 alkyl, C1-C4 alkoxy, carboxyl or protected carboxyl.
Also, when Ri is other than hydrogen, Formula I has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and SS, this invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR, which comprises reacting 1-[2- (2,4-disubstituted phenyl)-2,3-epoxy derivative of 1 ,2,4-triazole of Formula IV, wherein X, R and R1 f are the same as defined above, with triazol-3-one derivatives of Formula V, wherein R2,, R3, Xi, X2, Y, Yι, Y2 and Z have the same meanings, as defined above, in the presence of sodium hydride to afford the desired compound of Formula I A, wherein X, X1 2, Y-i, Y2. Z, R, R-i, R2 and R3 have the same meanings as defined above.
SCHEME IB
Figure imgf000015_0001
FORMULA E)
B=ON-R -
Figure imgf000015_0002
FORMULA IC
Figure imgf000015_0003
Figure imgf000015_0004
FORMULA E In Scheme IB there is provided a process for preparing a compound of Formula IB, wherein X, R, Ri, R2 ,R3 and Y are the same as defined above, R is selected from the group hydrogen, C-i - C4 alkyl group which is unsubstituted or substituted, B is selected from oxygen and sulphur atoms, R5 is selected from the group (1 ) hydrogen, (2) Ci- C4 alkyl group which is unsubstituted or substituted by 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (b) C1-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) C1-C-4 acyloxy (g) C1-C4 alkoxycarbonyl amino (h) phenyl or naphthyl- oxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl(r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C1-C4 alkyl) which may be substituted with
1-6 substituents selected from (a) Ci - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (b) halogen (c) (Cι-C4 alkyl) halo, (d) Cι-C4 alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetrafluoropropyl and
(m) tetrafluoropropoxyl.
Also, when R-i is other than hydrogen, Formula I has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and SS, this invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR, which comprises reacting a compound of Formula ID wherein X, R, Rι,R2, R3 and Y have the same meanings as defined earlier, with a compound of Formula R5 - N = C = B wherein R5 and B are the same as defined earlier to give a compound of Formula IC, which on reaction with R4Z wherein R is the same as defined above and Z is any halogen atom, gives a compound of Formula IB wherein X, R, R^ R2, R3, R4, R5, Y and B have the same meanings as defined earlier.
SCHEME II
Figure imgf000017_0001
FORMULA IA
In Scheme II, there is provided a process for preparing a compound of Formula IA, wherein X, R, R1 ( R2, R3, Y, Xi, X2, Yι, Y2 and Z are the same as defined above, also when R-i is other than hydrogen, Formula I has two asymmertric centres and there are four possible enantiomers i.e. RR, RS, SR and SS, this invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR, which comprises reacting epoxide derivative of Formula VI, wherein X, R, R1 ( R2, R3, X-i, X2, Y, Y-i, Y2 and Z are the same as defined above with 1 ,2,4-triazole to afford a compound of Formula IA.
SCHEME III
Figure imgf000018_0001
R5-N=OB
Figure imgf000018_0002
R4Z
Figure imgf000018_0003
FORMULA H There is provided a process for preparing a compound of Formula II, wherein X, R, R-i, R4, R5, Y and B have the same meanings as defined earlier, also when Ri is other than hydrogen, Formula II has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and SS, this invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR, which comprises reacting a compound of Formula VII, wherein R, R-i, X and Y are same as defined earlier with a compound R -N=C=B, wherein R and B are the same defined earlier to give a compound of Formula VIM, wherein R, R-i, R5, X, Y and B have the same meanings as defined earlier. The compound of Formula VIII, on reaction with R4Z, wherein R is C1-C4 alkyl and Z is any halogen atom, gives a compound of Formula II, wherein R, R-t, R4, R5, X, Y and B are the same as defined earlier.
SCHEME IV
Figure imgf000019_0001
FORMULA IX
BO€ΝTR
Figure imgf000019_0002
In scheme IV there is provided a process for the preparation of a compound of Formula III, wherein R, R-i, R5, X, Y and B are the same as defined above, also when Ri is other than hydrogen, Formula III has two asymmetric centres and there are four possible enantiomers i.e. RR, RS, SR and SS , this invention relates to the mixture of enantiomers as well as individual isomers and the most preferred isomer in this situation is RR, which comprises reacting a compound of Formula IX with a compound of Formula B=C=N-Rs wherein B and R5 are the same as defined earlier, to give the desired compound of Formula III.
SCHEME V
AlCb 1,2,4-Triazole
Figure imgf000021_0001
Figure imgf000021_0002
Figure imgf000021_0003
FORMULA X FORMULA XI FORMULA XII FORMULA Xm FORMULA IV
Figure imgf000021_0004
FORMULA XIV FORMULA XV
Figure imgf000021_0005
FORMULA XVI FORMULA XVπ
Figure imgf000021_0006
(X=CH 2, R=F, R ι=H, Y=C sH,-, R3=H) In Scheme V 1 ,3-difluorobenzene of Formula X, on treatment with chloroacetyl chloride of Formula XI, in the presence of a Lewis acid catalyst such
as aluminium trichloride gives α-choro-2, 4-difluoroacetophenone of Formula XII.
This compound of Formula XII is further reacted with 1 ,2,4-triazole to obtain 2- (1 H-1 ,2,4-triazol-1-yl)-2'-4'-difluoroacetophenone of Formula XIII. This compound of Formula XIII is further reacted with trimethyl sulphoxonium iodide (TMSI) to afford 1-[2-(2,4-difluorophenyl)-2, 3-epoxypropyl]-1 H-1 ,2,4-triazole of Formula IV (R=F, X=CH2, Rι=H). The procedure as described in US Patent 4,404,216 is followed to prepare compound of Formula IV.
The triazol-3-one derivatives of Formula V (R3 = H, Y=C6 H4 -), wherein R2,
Xι> X2, Y1 , Y2 and Z are the same as defined earlier, are prepared by reacting substituted phenyl piperazine of Formula XIV, wherein X1 f X2, Yι, Y2 and Z are the same as defined earlier, is reacted with 4-chloronitrobenzene to give the corresponding nitroaryl compound of Formula XV, which on catalytic reduction affords the anilino derivative of Formula XVI. The compound of Formula XVI, is acylated with phenyl chloroformate to afford phenyl carbamate derivatives of Formula XVII. Reaction of these carbamate derivative of Formula XVII, with hydrazine hydrate yields semicarbazide derivative of Formula XVIII, which on cyclization with formamidine derivatives gives the triazol-3-one derivatives of Formula V(R3 = H, Y=C6 H4 -). The reaction of compound of Formula V, with the compound of Formula IV (R=F, Rι=H, X=CH2) is carried out in the presence of sodium hydride to afford the desired compound of Formula IA (X=CH2, R=F, Rι=H, Y=C6H4-, R3=H), wherein R2, X-i, Xi, Y-i, Y2 and Z are the same as defined earlier. SCHEME NI
Figure imgf000023_0001
FORMULA XX
(X=CH 2, R=F, R , = CH 3j Y= C 6H4-, R3=H)
The compounds of Formula IA (X=CH2, R=F, Rτ= CH3, Y=C6H4-, R3=H) wherein R2, Xi, Yι,X2, Y2 and Z have the same meanings as defined earlier, are synthesized following the reaction sequence embodied in Scheme VI. Thus, 1 , 3-
difluorobenzene of Formula X is reacted with racemic (±) 2-chloropropionyl chloride of Formula XIX to give a compound (+) 2-chloro-2-methyl-2', 4'-difluoro-
acetophenone of Formula XX. The intermediate of Formula V which in turn is prepared by following the reaction sequence as described in Scheme V wherein
2, Xι> X2, Y-i, Y2 and Z have the same usual meanings, is condensed with (±)2-
chloro-2-methyl-2', 4'-difluoroacetophenone of Formula XX in the presence of sodium hydride to afford compound of Formula XXI, wherein R2, Xi, X2, Y1 Y2 and Z have the same meanings as defined earlier. The compound of Formula XXI is epoxidized with trimethylsulphoxonium iodide (TMSI) in dimethylsulfoxide (DMSO) to give an epoxide derivative of Formula VI (X=CH2, R=F, Rι=CH3, Y=C6H -, R3=H), which is then condensed with 1 ,2,4-triazole to give a compound of Formula IA (X=CH2, R=F, R.,= CH3, Y=C6H4-, R3=H), wherein R2l Xi, Yι, X2, Y2 and Z are the same as defined earlier.
SCHEME Nil
Figure imgf000025_0001
FORMULA VII (X=CH2, R=F, R^H, Y=C6H4 )
Figure imgf000025_0002
FORMULA VIE (X=CH2, R=F, Rι=H, Y=C6H4 )
Figure imgf000025_0003
FORMULA H (X=CH2, R=F, Rι=H, Y=C6H4 )
The compounds of Formula II (X=CH2, R=F, Rι=H, Y=C6H4-) wherein R4, R5| and B have the same meanings as defined earlier, are synthesized by following the reaction sequence as depicted above in Scheme VII. Thus, 2-(2,4- difluorophenyl)-3-(1 H-1 , 2,4-triazolyl)-1-[4-(piprazinyl) phenoxy]-propan-2-ol of Formula VII (X=CH2, R=F, R-i=H, Y=C6H4-) (prepared by the process as disclosed in US Patent No. 5,023,258, assigned to Pfizer) on treatment with the compound of Formula B=C=N-R5, wherein B and R5 ar the same as defined earlier gives a compound of Formula VIII (X=CH2, R=F, Rι=H, Y=C6H4-) wherein R5 and B are the same as defined earlier. This compound of Formula VIII (X=CH2, R=F, Rι=H, Y=C6H4-) is further reacted with R Z in the presence of sodium hydride gives the required compound of Formula II (X=CH2> R=F, Rι=H, Y=C6H4-), wherein R4, R5 and B are the same as defined earlier.
SCHEME NIII
Figure imgf000027_0001
FORMULA XXL!
Figure imgf000027_0002
Figure imgf000027_0003
FORMULA XXV
NaOH/Dioxane-HjO
Figure imgf000027_0004
Figure imgf000027_0005
Figure imgf000027_0006
FORMULA π (X=CH2, R=F, R,=CH3, R4=H, Y= H4- )
In Scheme VIII, 2-chloro-methyl-2',4'-difluoroacetophenone of Formula XXII, on treatment with 1-acetyl-4-hydroxyphenylpiperazine of Formula XXIII, gives 2-[4-(4-acetylpiperazine)phenoxy]-2-methyl-2',4'-difluoroacetophenone of Formula XXIV in the presence of potassium carbonate in dimethylformamide, which on treatment with trimethyl sulphoxonium iodide (TMSI) in DMSO gives the corresponding epoxide of Formula XXV. This compound of Formula XXV is reacted with 1 ,2,4-triazole to yield a compound of Formula XXVI, which in turn on hydrolysis with sodium hydroxide in dioxane gives a compound of Formula VII (X=CH2, R=F, Rι=CH3, Y=C6H4-). The compound of Formula VII on reaction with R5-N=C=B gives a compound of Formula II (X=CH2, R=F, Rι=CH3> R4=H) wherein R and B have the same meanings as defined earlier.
SCHEME IX
Figure imgf000029_0001
FORMULA IV FORMULA XXW FORMULA XXVm (R=F,X=CH2, R,=H)
Figure imgf000029_0002
FORMULA IX (X=CH2, R=F, R,=H, Y=C6H4-)
Figure imgf000029_0003
FORMULA IH (X=CH2l R=F, R,=H, Y=C6H4-)
In Scheme IX 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1 H-1 ,2,4-triazole of Formula IV (R=F, X=CH , Rι=H) on treatment with N-methyl-4-nitroaniline of Formula XXVII gives 3-[N-Methyl-N-(4-nitrophenyl)]-2-(2,4-difluorophenyl)-1-(1 H- 1 ,2,4~triazolyl)-propan-3-amino-2-ol of Formula XXVIII which on reduction with palladium on charcoal gives 3-[N-Methyl-N-(4-aminophenyl)]-2-(2,4-difluoro- phenyl)-1-(1 H-1 ,2,4-triazolyl)-propane-3-amino-2-ol of Formula IX, (X=CH2, R=F, R^H, Y=C6H4-) which on reaction with B=C=N-R5 gives a compound of Formula III (X=CH2) R=F, Rι=H, Y=C6H -) wherein B and R5 are the same as defined earlier. In the above schemes where specific acids, bases, solvents, catalysts,
oxidising agents, reducing agents etc. are mentioned, it is to be understood that
the other acids, bases, solvents, catalysts, oxidising agents, reducing agents etc.
may be used. Similarly, the reaction temperature and duration of the reaction
may be adjusted according to the need.
An illustrative list of particular compounds according to the invention and
capable of being produced by Schemes IA, IB to IX include:
Compound
No. Chemical Name
1. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(4-chlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
2. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(4-chlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
3. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 -yl) propyl}-4-{4-[4-(2,4-dinitrophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone 4. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(2,4-dinitrophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone 5. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-[4-(1 -phenylpiperazinyl)phenyl]-3-(2H,4H)-1 ,2,4-triazolone 6. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(1-phenylpiperazinyl) phenyl}-3-(2H,4H)-1 ,2,4-triazolone 7. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(3,4-dichlorophenyl)-1 -piperzinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone 8. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(3,4-dichlorophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone 9. 2-{[1 R2R/1 S2S]~2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(3-trifluoromethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
10. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(3-trifluoromethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
11. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone 12. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-l - yl) propyl}-4-{4-[4-(4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
13. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-l - yl) propyl}-4-{4-[4-(4-methoxyphenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
14. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4-triazol-l - yl) propyl}-4-{4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
15. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(3-chloro-4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
16. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(3-chloro-4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone 17. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(3-chloro-4-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone
18. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-l - yl) propyl}-4-{4-[4-(3-chloro-4-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone
19. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(2,4-dimethylphenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
20. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(2,4-dimethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone 21. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(5-chloro-2-methyIphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-
1 ,2,4-triazolone
22. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(5-chloro-2-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-
1 ,2,4-triazolone
23. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(3,4-dimethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl- 1 ,2,4-triazolone 24. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(3,4-dimethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl- 1 ,2,4-triazolone
25. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(2-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl- 1 ,2,4-triazolone
26. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(2-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl- 1 ,2,4-triazolone
27. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(2-methoxy-5-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5- methyl-1 ,2,4-triazolone
28. 2-{[1R2S/1S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1- yl) propyl}-4-{4-[4-(2-methoxy-5-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5- methyl-1 ,2,4-triazolone 29. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(3,5-dichlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl- 1 ,2,4-triazolone
30. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-l - yl) propyl}-4-{4-[4-(3,5-dichlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl- 1 ,2,4-triazolone
31. 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(2-ethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-1 ,2,4- triazolone
32. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(2-ethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-1 ,2,4- triazolone 33. 2-{[1 R2R 1 S2S]-2-(2,4-Difluorophenyl)-2-hydraxy-1-methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(2,4-dichlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl- 1 ,2,4-triazolone
34. 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(2,4-dichlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-
1 ,2,4-triazolone
35. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2- methoxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-1 ,2,4-triazolone
36. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-1 ,2,4-triazolone
37. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(3,4- dichlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
38. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2,4- diaminophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone 39. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-{4-[4-(4- methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
40. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2,4- dinitrophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
41. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1-yl)propyl]-4-{4-[4-(4- methoxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
42. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2- methoxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
43. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone 44. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- hydroxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
45. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-[4-[1 - phenylpiperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
46. 2-[2-(2,4-Difluoropheny!)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1-yl)propyl]-4-{4-[4-(4- chlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-1 ,2,4-triazolone
47. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-l -yl)propyl]-4-{4-[4-(4- chlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
48. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1-yl)propyl]-4-{4-[4-(5- chloro-2-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone 49. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1-yl)propyl]-4-{4-[4-(3- chloro-4-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone 50. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2,4- dichlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
51. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(3- trifluoromethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone 52. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-l -yl)propyl]-4-{4-[4-(2,4- difluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
53. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(3- chloro-4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
54. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2,4- dimethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
55. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -y|)propyl]-4-{4-[4-(3,4- difluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
56. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-l -yl)propyl]-4-{4-[4-(3,4- dimethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone 57. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-
{4-[4-(3-chlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
58. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-l -yl)propyl]-4- {4-[4-(2-chloro-4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
59. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4- (2- methoxy-5-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
60. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-l -yl)propyl]-4- {4-[4-(2-ethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
61. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4- {4-[4-(3,5-dichlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone 62. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-l -yl)propyl]-4-
{4-[4-(2-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
63. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4- {4-[4-(2,3,4-trifluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
64. 3-{4-[4-(p-Tolylthioureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-1 -(1 H-1 ,2,4- triazol-1-yl)-propan-2-ol.
65. 3-{4-[4-(lsopropylaminothiocarbonylamino)piperazinyl]phenoxy}-2-(2,4- difluorophenyl)-1-(1 H-1 ,2,4-triazoM -yl)-propan-2-ol.
66. 3-{4-[4-(4-Chlorophenylthioureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-1- (1 H-1 ,2,4-triazol-1 -yl)-propan-2-ol. 67. 3-{4-[4-(4-Chlorophenylureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-1-(1 H-
1 ,2,4-triazoM -yl)-propan-2-ol. 68. 3-{4-[4-(1 -Napthylthioureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-1 -(1 H- 1 ,2,4-triazoM -yl)-propan-2-ol.
69. 3-{4-[4-(1-Napthylureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-1-(1 H-1 ,2,4- triazoM -yl)-propan-2-ol. 70. 3-{4-[4-(4-Trifluoromethylphenyl thioureido)piperazinyl]phenoxy}-2-(2,4- difluorophenyl)-1 -(1 H-1 ,2,4-triazoM -yl)-propan-2-ol.
71. 3-{4-[4-(4-Methoxyphenylureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-1- (1 H-1 ,2,4-triazol-1 -yl)-propan-2-ol.
72. 3-{4-[4-(2,4-Dichlorophenylureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-1- (1 H-1 ,2,4-triazoM -yl)-propan-2-ol.
73. 3-{4-[4-(4-Chlorophenyl-N-ethylureido)-piperazinyl ]-phenoxy)-2-(2,4- difluorophenyl)-1 -(1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol
74. 3-{4-[4-(4-Chlorophenyl-N-ethylureido)-piperazinyl ]-phenoxy)-2-(2,4- difluorophenyl)-1 -(1 H-1 ,2,4-triazolyl)-2-ethoxy-3-propane. 75. 3-{4-[4-N-(4-Chlorophenyl)-N-(methylureido)-piperazinyl]-phenoxy}-2-(2,4- difluorop enyl)-l-(lH-l,2,4-triazolyl)-2-met oxypropane.
76. 3-{4-[4-(4-Aminophenylureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-1 -(1 H- 1 ,2,4-triazoM -yl)-propan-2-ol.
77. [1 R2R/1 S2S] 1 -{4-[4-(4-Chlorophenylureido)-piperazinyl ]-phenoxy}-2-(2,4- difluorophenyl)-1 -methyl -3-(1 H-1 ,2,4-triazolyl)-propan-2-ol
78. [1 R2S/1 S2R] 1 -{4-[4-(4-Chlorophenylureido)-piperazinyl ]-phenoxy}2-(2,4- difluorophenyl)-1 -methyl -3-(1 H-1 ,2,4-triazolyl)-propan-2-ol
79. 1-{4-[4-(4-Trifluoromethylphenylureido)piperazinyl]phenoxy}-2-(2,4- difluorophenyl)-1 -methyl-3-(1 H-1 ,2,4-triazol-1 -yl)-propan-2-ol. 80. 3-{4-[4-(Phenylureido)-piperazinyl ]-phenoxy}-2-(2,4-difluorophenyl)-1 -(1 H-1 ,2,4- triazoM -yl)-propan-2-ol.
81. 3-{N-[4-(Phenylthioureido)-phenyl]- N-methyl}-2-(2,4-difluorophenyl)-1 -(1 H-1 ,2,4- triazolyl)-propan-3-amino-2-ol
82. 3-{N-[4-(lsopropylthioureido)-phenyl]- N-methyl}-2-(2,4-difluorophenyl)-1 -(1 H- 1 ,2,4-triazolyl)-propan-3-amino-2-ol
83. 3-{N-[4-(p-Tolylthioureido)-phenyl]- N-methyl}-2-(2,4-difluorophenyl)-1 -(1 H-1 ,2,4- triazolyl)-propan-3-amino-2-ol
84. 3-{N-[4-(p-Fluorophenylureido)-phenyl]- N-methyl}-2-(2,4-difluorophenyl)-1 -(1 H- 1 ,2,4-triazolyl)-propan-3-amino-2-ol 85. 3-{N-[4-(p-Nitrophenyltureido)-phenyl]- N-mefhyl}-2-(2,4-difluorophenyl)-1-(1 H-
1 ,2,4-triazolyl)-propan-3-amino-2-ol 86. 3-{N-[4-(p-Chlorophenylureido)-phenyI]- N-methyl}-2-(2,4-difluorophenyl)-1 -(1 H- 1 ,2,4-triazolyl)-propan-3-amino-2-ol
87. 3-{N-[4-(Carboxymethyl)-phenyltureido)-phenyl]- N-methyl}-2-(2,4-difluorophenyl)- 1-(1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol 88. 3-{N-[4-(2-Methoxy-2-oxoethyl)-phenyltureido)-phenyl]- N-methyl}-2-(2,4- difluorophenyl)-1 -(1 H-1 ,2,4-triazolyl)~propan-3-amino-2-ol
89. 3-{N-[4-(p-Chlorophenylthiouredo)-phenyltureido)-phenyl]- N-methyl}-2-(2,4- difluorophenyl)-1 -(1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol
90. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4- (isopropylthiouredio)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
91. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-l -yl)propyl]-4-{4-[4-(4- chlorophenyluredio)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
92. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- chlorophenylthiouredio)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone 93. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4-(2- methoxy-2-oxoethyl)phenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
94. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- (carboxyethyl)-phenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
95. 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4-(2- hydroxyethyl)phenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
Preferred group of compounds belonging to the compounds of Formulae
IA, IB, II and III of the present invention are exemplified in Table I to Table IV
though the present invention is not limited to the compounds given there.
TABLE I FORMULA IN (X=CH2ϊ R=F, Y=C6H4-, R3=H)
LIST OF α-METHYL ANALOGUES
Figure imgf000037_0001
LIST OF non- α-METHYL ANALOGUES
Figure imgf000038_0001
TABLE - II (FORMULA II)
(X = CH2, R= F, Y= C6H4-)
Figure imgf000039_0001
TABLE - III (FORMULA III) (X = CH2,R=F,Y=C6H4-)
Figure imgf000040_0001
TABLE - IV (FORMULA IB) (X = CH2, R= F, Y= C6H4-, R1s R2, R3 and R4=H)
Figure imgf000040_0002
All compounds mentioned in the above list as well as the compounds mentioned in formulae IA, IB, II and III with a variety of substituents were prepared using the methods described earlier depending upon whether they are
mixtures of α-methylated isomers, mixtures of non α-methylated isomers or pure
RR isomers.
The examples mentioned below demonstrate the general synthetic procedure as well as the specific preparation for the preferred compound. The examples are given to illustrate the details of the invention and should not be constrained to limit the scope of the present invention.
Most of the compounds were characterized using NMR, IR and were purified by chromatography. Crude products were subjected to column chromatographic purification using silica gel (100 -200 or 60-120 mesh) as stationary phase.
EXAMPLE 1
Preparation of 2-{2-[(2,4-Difluorop enyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM - yl)propyl]}-4-{[4-[4-(substituted/unsubstituted phenyl)-1 - piperazinyl]phenyl]}-3-(2H, 4H)-1 ,2, -substituted triazol-4-one.
Step 1 : Preparation of 2-chloro-2', 4'-difluoro acetophenone.
Into the solution of 1 ,3-difluorobenzene in 1 ,2-dicholoroethane (DCE) was added anhydrous aluminium chloride (1.2 molar equivalent of 1 ,3- difluorobenzene) at 25-30°C and stirred for 30 minutes. The reaction mixture was then cooled to 0°C and chloroacetyl chloride (1.1 molar equivalent of 1 ,3- difluorobenzene), in DCE, was then added into it over a period of 30-60 min keeping the reaction temperature below 20°C. After the addition was over, the reaction mixture was stirred at 25-30°C for 5-7 hours. The reaction mixture was then diluted with DCE and poured into dil. hydrochloric acid (5%) at 0-5°C. The mixture was then extracted with DCE. The combined organic layer was washed successively with 5% aq. sodium bicarbonate solution and water. Evaporating DCE from the organic layer under reduced pressure gave an oil which on triturating with n-Hexane gave the title compound as white crystalline material (Yield 75% of theory).
Step 2: Preparation of 2-(1 H,2,4-triazol-1-yl)-2',4'-difluoro acetophenone
The product obtained in Step -1 was reacted with 1 ,2,4-triazole (1.2 molar equivalent) in the presence of sodium bicarbonate as base and toluene as solvent under refluxing condition. After the reaction was over, the reaction mixture was poured into crushed ice and extracted with toluene. The combined organic layer was then washed with water and concentrated under reduced pressure to give brown semisolid compound which was recrystallized from ethyl acetate - hexane mixture to give light yellow solid compound which was then used as such in the next step.
Step 3: Preparation of 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1 H-1 ,2,4- triazole
Step 2 product was dissolved in toluene, followed by the addition of trimethylsulfoxonium iodide (TMSI), cetramide and 20% aq. sodium hydroxide solution. This mixture was then heated at 60° C for 4 hrs. After the reaction was over, it was diluted with toluene and poured into chilled water. The organic layer was washed with water and concentrated under reduced pressure to give light brown oil which was used after column chromatographic purification (silica gel) in the next step.
Step 4: Preparation of 1 -(substituted phenyl)-4-(4-nitrophenyl) piperazine.
Substituted phenyl piperazine was reacted with 4-chloronitrobenzene (1.1 molar equivalent of phenyl piperazine) in dimethylsulphoxide [DMSO] (5 times) using anhydrous potassium carbonate (1.5 molar equivalent) at a temperature
135-140° C for 6 to 8 hrs. The reaction mixture was poured into crushed ice and the compound was isolated either as a solid or by extracting with chlorinated organic solvent. After drying under vacuum at 30-35°C for 6-8 hrs, the compound was used as such for next step.
Step 5: Preparation of 1 -(substituted phenyl)-4-(4-aminophenyl)piperazine
The nitro compound was then reduced to amine by two methods:
Method 1 : The compound of Step 4 was dissolved in methanol and Palladium on charcoal (wet, 10% w/w) was added under nitrogen followed by the addition of ammonium formate (5 molar equivalent). The reaction mixture was
then stirred at a temperature ranging from 45 to 70 °C until the reaction went to completion. After the reaction was over, the reaction mixture was then cooled to
25-30°C and filtered. The filtrate was then concentrated under reduced pressure to give a residue which was again dissolved in dichloroethane and washed with water. The organic layer on concentration gave the desired product. Method 2: The compound of Step 4 was refluxed in ethyl acetate in the presence of 5.0 molar equivalent stannous chloride dihydrate for 6-8 hrs. After completion of the reaction, the reaction mixture was poured into 10% aq. sodium bicarbonate and extracted with ethyl acetate. The combined organic layer was then washed with water dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the desired product.
Step 6: Preparation of [4-(4-(substituted/unsubstituted phenyl) -1 -piperazinyl] phenyl carbamate
The amine obtained from Step 5 was dissolved in a mixture of dichloroethane (DCE) and pyridine and cooled to 5°C. A solution of phenylchloroformate (1.4 molar equivalent) in DCE was added into the solution of
amine at such a rate that reaction temperature remained below 35°C. After the addition was over, reaction mixture was stirred at 25-30°C for 3-5 hours. Solvent was evaporated off under reduced pressure to give brownish residue which on triturating with n-hexane gave brown solid. It was then obtained was washed with 5% aq. solution of sodium bicarbonate and water. It was then dried under
vacuum at 40 °C for 3 to 5 hrs to give the corresponding carbamate.
Step 7: Preparation of N-[4-[(4-substituted phenyl) 1-piperazinyl]phenyl]hydrazine carboxamide.
The carbamate obtained in Step 6 was stirred in 1 ,4-dioxane followed by the addition of hydrazine hydrate (2.5 molar equivalent 98%) at room temperature. After refluxing the reaction mixture for 4 to 6 hrs, solvent was evaporated off to give solid residue which was triturated with 10% methanol in diethyl ether, filtered the separated solid and dried under vacuum at 35 -40°C for 4 to 6 hrs to give corresponding semicarbazide.
Step 8: 4-(4-Substituted phenyl)-1-piperazin]phenyl-3H-1 ,2,4-triazol-3-ones.
The semicarbazide so obtained was dissolved in dry dimethylformamide
(DMF) followed by the addition of formamidine acetate (4.5 molar equivalent). After heating at 120 - 130°C for 3 to 5 hrs, reaction mixture was poured into chilled saturated aq. solution of sodium bicarbonate with stirring. Solid so obtained was filtered, washed with water and dried under vacuum at 40°C for 7 hrs. to give corresponding triazolone.
Step 9: Preparation of 2-[(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)- propyl]-4-[4-[4-substitutedphenyl-1-piperazinyl]phenyl]-3-(2H,4H)-1 ,2,3- substituted triazol-4-one.
Hexane washed sodium hydride (0.015 mg, 1.0 mmol) was added into a stirred solution of compound obtained from Step -8 (0.4g, 1.12 mmol) in dimethyl formamide (DMF) (10 ml) maintaining nitrogen atmosphere. After stirring at 25- 30°C, a solution of the compound obtained from Step 3 (1.68mmol) in DMF was
added drop-wise into the reaction mixture at 40°C, temperature was raised to
80°C and maintained at this temperature for about 4 hr. After the reaction was over, reaction mixture was cooled to 35-40°C, poured it into chilled water (50 ml) and extracted with ethyl acetate (3x 100ml). The combined organic layer was washed with water (4x50ml), dried over anhydrous sodium sulphate and concentrated under vacuum to give an oily residue (0.3 gm). The oil was purified by column chromatography (silica gel 100-200 mesh) using hexane-ethyl acetate (1 :1 ) followed by ethyl acetate or by crystallisation from suitable solvent to give the required compound.
EXAMPLE 2
Preparation of 2-{[1 R.2R/1 S,2S/1 R,2S/1 S,2R]2-[(2,4-Difluorophenyl)-2- hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM -yl) propyl]}-4-{[4-[4-substituted /unsubstituted)phenyl-1-piperazinyl]phenyl]}- 3- (2H, 4H)-1, 2, 3- substituted triazol -4-one.
Step 1 : Preparation of 2-chloro-2-methyl-2',4'-difluoro acetophenone
Into the solution of 1 ,3-Difluorobenzene in 1 ,2-dicholoroethane (DCE) was added anhydrous aluminium chloride (1.2 mol eqnt.) at 25-30°C and stirred for 30 minutes. The reaction mixture was then cooled to 0°C and (+) 2-chloropropionyl chloride (1.1 molar equivalent), diluted in DCE , was then added into it over a
period of 30-60 min keeping the reaction temperature below 20°C. After the addition was over, reaction mixture was stirred at room temperature for 5-7 hours. For workup, reaction mixture was diluted with DCE and poured into chilled aq. hydrochloric acid solution (5%). The mixture was extracted with DCE and the combined organic layer was washed with 5% aq. sodium bicarbonate solution and water. The solvent was evaporated off under reduced pressure to afford an oil. Step 2: Preparation of 2-{[4-[4-[4-(substituted/unsubstituted phenyl)piperazin- yl]phenyl-(2H,4H)-1 ,2,4-triazol-3-one-2-yl]}-2(R/S)-methyl-2',4'- difluoroacetophenone
Hexane washed sodium hydride (1.2 molar equivalent) was added into a stirred solution of compound of Formula XII (1.0 molar equivalent) in dimethylsulphoxide (DMSO) maintained under nitrogen atmosphere. After stirring at 25-30°C for 1 hr, a solution of the compound of Formula XIV (2 molar equivalent) in DMSO was added dropwise into the reaction mixture at about 15°C. The reaction mixture was then stirred at 25-30°C for 2 hrs and slowly the
temperature was raised to 60 °C and maintained this temperature for 3-4 hrs. After the reaction was over, reaction mixture was cooled to 25-30°C, poured into chilled water and extracted with ethyl acetate. The combined organic layer was washed with water, dried over anhydrous sodium sulphate and concentrated to give an oily residue under vacuum. The crude product was purified by column chromatography (silica gel 100-200 mesh) using hexane-ethyl acetate (1 :1) followed by using ethyl acetate to give the required compound.
Step 3: Preparation of 2-{[1 (R/S)-methyl-2-(2',4'-difluorophenyl)-2,3-epoxy- propyl]-4-[4-(substituted phenyl)piperazinyl]phenyl]}-3-(2H,4H)-1 ,2,4-substituted thiazolone.
Hexane washed sodium hydride was stirred in DMSO followed by the
addition of trimethylsulfoxonium iodide (TMSI) at 15 °C. The reaction mixture was stirred at 25-30°C under nitrogen atmosphere for 1-2 hrs. A solution of the compound obtained in Step 2 in DMSO was added into the above mixture at 25-
30°C and then heated to 80 to 90 °C for 1-2 hrs. Due to the generation of second chiral center in the molecules two pairs of diasteromers were formed which were detected both by TLC as well as by HPLC methods. After the reaction was over the reaction mixture was cooled to 25-30°C, poured into chilled brine and extracted with ethyl acetate. The combined organic layer was washed with water, dried over sodium sulfate and concentrated under vacuum to give either an oil or a fluffy solid which was then used as such for the next step.
Step 4: Preparation of 2-{[1 R,2R/1S,2S/1 R,2S/1S,2R]2-[(2,4-Difluoro phenyl)-2- hydroxy-3-methyl-3-(1 -H-1 ,2,4-triazoM -yl)propyl]}-4-{4-[4- (substituted/unsubstituted phenyl)-1-piperazinyl]phenyl]}-3-(2H,4H)-1 ,2,3- substituted triazol-4-one].
1 ,2,4-Triazole was stirred with sodium hydride in dimethylformamide (DMF) at 25-30°C for about 1 hr. The solution of epoxide obtained from step-3 in DMF was then added into this reaction mixture at 25-30°C and stirred the
reaction mixture at 100°C. After the reaction was over the reaction mixture was cooled to 25-30°C, poured into chilled brine and extracted with ethyl acetate. The combined organic layer was washed with water, dried over anhydrous sodium sulfate and concentrated under vacuum to give either an oil or a fluffy solid. Compound so obtained was actually a mixture of four isomers showing two spots on TLC. The mixtures of diastereomers was then separated by preparative
HPLC. EXAMPLE 3
Preparation of 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM - yl)propyl]-4-{4-[4-(5-chloro-2-methylphenyl)-1 -piperazinyI]phenyl}-3-(2H,4H)-
1,2,4-triazolone
5-Chloro-2-methyl-phenylpiperazine (20. Og) was reacted with 4- chloronitrobenzene (16.0g) in dimethylsulphoxide (DMSO) (110ml) in the presence of anhydrous potassium carbonate (19.9g) at a temperature of 135-
140°C for 8 hours. After the reaction was over (TLC monitoring), the reaction mixture was poured into crushed ice and the compound was isolated as an orange solid. After drying under vacuum at 25-30°C for 6-8 hours, the nitro compound (29. Og, orange solid; m.p. 146-150°C) was used as such for the next step.
The nitro compound (18.0g) was refluxed in ethyl acetate (150ml) in the presence of stannous chloride dihydrate (55.5g) for 8 hours. After completion of the reaction, the reaction mixture was poured into 10% aqueous sodium bicarbonate (500ml) and extracted with ethyl acetate (3 x 150ml). The combined organic layer was washed with water (3 x 100ml) and then dried over anhydrous sodium sulfate. The organic layer was concentrated under vacuum to give the desired amine (15.3g, brown oil; yield:93%).
The amine (15.0g) was dissolved in a mixture of dichloroethane (DCE)
(80ml) and pyridine (30ml). The reaction mixture was cooled to about 15°C. A solution of phenylchloroformate (11.67g) in DCE (10ml) was added into the solution of amine at such a rate that reaction temperature remained below 20°C. After the addition was over, reaction mixture was stirred at 25-30°C for about 3 hours. Solvent was evaporated off under reduced pressure to give brownish residue which on triturating with n-hexane (150ml) gave brown solid. Solid was washed with n-hexane (2x100ml), 5% aq. solution of sodium bicarbonate (2 x 100ml) and distilled water (2x150ml) followed by drying under vacuum at 40°C for 5 hours to give 10gm of corresponding carbamate (Yield 86%) m.p.201-205°C.
The carbamate (18.0g) was stirred in 1 ,4-dioxane (130ml) followed by the addition of hydrazine hydrate (98%) (5.32g) at 25-30°C. After refluxing the reaction mixture for 4 hours, solvent was evaporated off to give solid residue which was triturated with 10% methanol in diethyl ether (150ml). The separated solid was filtered, washed and dried under vacuum at 35°C for 4 to 6 hours to give corresponding semicarbazide (15.5g) mp 177-182°C.
The semicarbazide (5.0g) was stirred in dry DMF (25ml) followed by the addition of formamidine acetate (6.5g). After heating at 120°C for 3 to 5 hours, the reaction mixture was poured into a chilled saturated aq. solution of sodium bicarbonate (100ml) with stirring. Solid so obtained was filtered, washed with water (3 x 50ml) and dried under vacuum at 40°C for 5 hours to give corresponding triazolone derivative (4.3g, 84%) as a brown amorphous solid; mp 258-262°C.
Hexane washed sodium hydride (0.057g, 60% suspension in oil) was added into a stirred suspension of the above triazolone intermediate (0.5g) in
DMF (10ml) maintained under nitrogen atmorphere. After stirring at 25-30°C, a solution of the epoxide interemdiate (0.48lgm) in DMF (5ml) was added dropwise into the reaction mixture at 40°C. Temperature was then raised to 80°C and maintained for about 4 hr. Reaction mixture then was cooled to 25-30°C, poured into chilled water (50ml) and extracted with ethyl acetate (3 x 100ml). The combined organic layer was washed with water (4x50ml), dried over anhydrous sodium sulphate and concentrated under vacuum to give an oily residue (0.3gm). The oily residue was subjected to column chromatography (silica gel 100-
200mesh) using hexane-ethyl acetate (1 :1 , 300ml) followed by ethyl acetate (500ml) to give the required compound. (0.481 gm, 57%) mp 82-91°C.
EXAMPLE 4
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-1 -yl) propyl}-4-{4-[4-(5-chloro-2-methylphenyl)-1 -piperazinyl]phenyl}-
3-(2H,4H)-1 ,2,4-triazolone (Compound No. 21)
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazoM -yl) propyl}-4-{4-[4-(5-chloro-2-methylphenyl)-1 -piperazinyljphenyl}- 3-(2H,4H)-1 ,2,4-triazolone (Compound No. 22)
Step 1 : Preparation of 2-{4-[4-[4-(2-methyl-5-chlorophenyl)piperazinyl]phenyl}- (2H,4H)-1 ,2,4-triazol-3-one-2-yl}-2(R/S)-methyl-2,4-difluoroacetophenone.
Hexane washed sodium hydride (0.311g) was added into a stirred solution of triazolone intermediate (4-[4-(2-methyl-5-chlorophenyl)-1-piperazinyl]phenyl-1-
(3-(2H,4H)-1 ,2,4 triazolone (2.5g) in DMSO (25ml) maintained under nitrogen atmosphere. After stirring at 25-30°C for 1 hour, a solution of the intermediate of Formula XIV (2.77g) in DMSO (5ml) was added dropwise into the above reaction mixture at 15°C. The reaction mixture was then stirred at 25-30°C for 2 hours, slowly the temperature was raised to 60°C and maintained for 3-4 hours.
Reaction mixture was cooled to 25-30°C, poured into chilled brine (150ml) and extracted with ethyl acetate (3 x 100ml). The combined organic layer was washed with water (4 x 50ml), dried over anhydrous sodium sulphate and concentrated to an oily residue under vacuum. The crude oil was subjected to column chromatography (silica gel 100-200mesh) using hexane -ethyl acetate (1 :1 ) followed by ethyl acetate to give required compound in pure form (2.6gm; 71 %) mp 125-128°C.
Step 2: Preparation of 2-[1-(R/S)-methyl-2-(2'-4'-difluorophenyl)-2,3-epoxy- propyl]-4-{4-[4-(5-chloro-2-methylphenyl)piperazinyl]phenyl]}-3-(2H,4H)-1 ,2,4- triazolone.
Hexane washed sodium hydride (0.128g) was stirred in DMSO (15ml) followed by the addition of trimethylsulfoxonium iodide (TMSI) (0.736g) at 15°C. The reaction mixture was stirred at 25-30°C under nitrogen atmosphere for 1 hr. A solution of Step 1 product (0.9g) in DMSO (5ml) was added into the above reaction mixture at 25-30°C and then heated to 80 to 90°C for about 1 hr. Due to generation of second chiral centre in the molecule, two pairs of diastereomers were formed which were detected by the TLC and by HPLC analyses. After the reaction was over, the reaction mixture was cooled to 25-30°C, poured into chilled brine and extracted with ethyl acetate (3 x 75ml). The combined organic layer was the washed with water (2 x 50ml), dried over sodium sulfate and concentrated under vacuum to give an oil (0.93gm, 100%) which was then used as such immediately for next step. Step 3: 2-{[1 R2R/1 S2S]-2-(2,4-Difluoropheny!)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazoM -yl) propyl}-4-{4-[4-(5-chloro-2-methylphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No. 21 )
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(5-chloro-2-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-
1 ,2,4-triazolone (Compound No. 22)
1 ,2,4-Triazole (0.232g) was stirred with anhydrous potassium carbonate (0.465g) in DMF (10ml) at 25-30°C for 1-2 hours. A solution of epoxide obtained from Step-2 (0.925g) in DMF (3.0ml) was then added into the above mixture at
25-30°C followed by heating the reaction mixture at 90 to 100°C for 1 hr. After the reaction was over, reaction mixture was cooled to 25-30°C, poured into chilled brine (70.0ml) and extracted with ethyl acetate (3 x 75ml). The combined organic layer was washed with water (2x250ml), dried over sodium sulfate and concentrated under vacuum to give an oil. Compound obtained actually was a mixture of two pairs of diastereomers showing two spots on TLC (Ethyl acetate). The mixture of diastereomers (0.613g, 59%) was then separated by column chromatography to get compound no.21 ) (faster moving spot on TLC) (35mg), compound no.22 (slower moving spot on TLC) and 550mg of mixture of the two spots.
EXAMPLE 5
Preparation of 3-[4-(4-Chlorophenylthioureido)N-methyl-N-phenyl]-2-(2,4- difluorophenyl)-1 -(1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 89)
Step 1 : Preparation of 3-[N-methyl-N-(4-nitrophenyl)]-2-(2,4-difluorophenyl)-1- (1 H-1 ,2,4-triazolyl)- propan-3-amino-2-ol.
Into a stirred suspension of sodium hydride (42 mg) in dry dimethylformamide (DMF) (5.0 ml) was added N-methyl-p-nitroaniline (1.5 gm) at
5-10°C. The resulting suspension was stirred at 30°C for 1 hour followed by the
addition of a solution of epoxide (Formula IV) in DMF (2.0 ml) at 5-10°C.
Reaction mixture was then stirred at 30°C for 30 min, heated to 60-65°C for 12
hrs and was cooled to 30°C. Poured the reaction mixture into ice-water mixture and extracted with dichloromethane (3x100 ml). The combined organic layer was washed with DM water (2 x 70 ml), dried over sodium sulphate and concentrated
under reduced pressure to give a yellow solid (2.1 g, m.p. 248-50°C).
Step 2: Preparation of 3-[N-methyl-N-(4-aminophenyl)]-2-(2,4-difluorophenyl)-1- (1 H-1 ,2,4-triazolyl)- propane-3-amino-2-ol.
Into a stirred solution of Step 1 product in methanol was added palladium on carbon (10%) (50% w/w) (0.5 g) under nitrogen atmosphere. The suspension
was then cooled to 10°C followed by the addition of ammonium formate (1.2 g) in portions over a period of 15 min. The reaction mixture was then heated to reflux
and stirred at reflux for 5 hours. Reaction mixture was cooled to 30°C and filtered through a celite pad. The combined filtrate was concentrated under vacuum to give a yellow semi-solid which was redissolved in dichloromethane (200 ml). The organic layer was washed with DM water (3 x 100 ml), dried over sodium sulfate and concentrated under reduced pressure to give semi-solid amine which was subjected to next step without further purification.
Step 3: Preparation of 3-[4-(4-Chlorophenylthioureido)N-methyl-N-phenyl]-2-(2,4- difluorophenyl)-1-(1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 89)
Dissolved the amine (Step-ll product) (400 mg) in anhydrous acetonitrile (5 ml) and added p-chlorophenyl isothiocyanate (227 mg, 1.2 eqm) to it. Stirred for 4 hours at 25-30°C and the solvent was evaporated off to afford residue which was purified using column chromatography (Yield: 200 mg, 34%).
EXAMPLE 6
Preparation of 3-{4-[4-N-(4-chlorophenyl)-N-(methylureido)-piperazinyl ]- phenoxy}-2-(2,4-difluorophenyl)-1 -(1 H-1 ,2,4-triazolyl)-2-methoxypropane (Compound No. 75)
Dissolved the amine of Formula VII (prepared by following the process as described in US Patent No. 5,023,258) (9 g) in anhydrous acetonitrile (50 ml) and added p-chlorophenyl isocyanate (4 g) to it. Stirred the reaction mixture for 1 hr at 25-30°C and evaporated the solvent to afford crude oil which was purified using column chromatography (Yield: 8.3 g, 75%). EXAMPLE 7
Preparation of [1 R2R/1S2S] 1-{4-[4-(4-chlorophenylureido)-piperazinyl ]- phenoxy}-2-(2,4-difluoropheny!)-1 -methyl -3-(1 H-1 ,2,4-triazoIyl)-propan-2-ol (Compound No. 77) and
[1 R2S/1 S2R] 1 -{4-[4-(4-chlorophenylureido)-piperazinyl ]-phenoxy}-2-(2,4- difluorophenyl)-1 -methyl -3-(1 H-1,2,4-triazolyl)-propan-2-ol (Compound No. 78)
Step 1 : Preparation of 2-{4-[4-acetyl-1 -piperazinyl]-phenyl]-2(R/S)-methyl-2,4- difluoroacetophenone
A solution of 2-chloro-2(R/S)-methyl-2,4-difluoroacetophenone(10.5 g) (1.5 molar equivalent) in dry dimethylformamide (DMF) was added into a stirred suspension of 1-acetyl-4-hydroxyphenylpiperazine (8.0 g) and potassium
carbonate (12.16 g) in dimethylformamide (DMF) at 5-10°C. Reaction mixture
was then stirred at 30°C for 20 min, heated to 60°C and stirred at 60°C for about 5 hrs. Reaction mixture then was cooled to 25-30°C, poured into ice-water mixture and extracted with ethyl acetate (3 x 200 ml). The combined organic layer was washed with water (3 x 100 ml), dried over sodium sulfate and concentrated under reduced pressure to get foamy product (8.0 g; 71 %).
Step 2: Preparation of 1-(R/S)-methyl-2,3-epoxypropyl-2-{4-[(4- acetylpiperazinyl)] phenoxy}-2-(2',4'- difluorobenzene)
Into a stirred suspension of sodium hydride (1.97 g) in dry dimethylsulphoxide (DMSO) under nitrogen atmosphere was added
trimethylsulfoxomium iodide (9.075 g) at 10-15°C. The foaming suspension was stirred at 30°C for 1 hr followed by the addition of a solution of Step-I product (8.0
g) in DMSO at 10-15°C over a period of 10 min. Reaction mixture was then
heated to 90°C and stirred at 90°C for about 4 hours. Cooled the reaction mixture, poured it into ice-water mixture and extracted with ethyl acetate (3 x 200 ml). The combined organic layer was then washed with water (3x150 ml), dried over sodium sulphate and concentrated under reduced pressure to give foamy product (7.0 g; 85%).
Step 3: Preparation of 1-{4-[4-Acetylpiperazinyl)-phenyl]-2-(2,4-difluorophenyl)- 1 (R/S)- methyl-3-(1 H-1 ,2,4- triazolyl)-propane-2-ol)]
Into a stirred suspension of sodium hydride(1.67 g) in dry dimethylformamide (DMF), was added 1 ,2,4-triazole (2.4 g) under nitrogen
atmosphere and stirred at 30°C for 1 hour. A solution of Step 2 product (7.0 g) in
DMF was then added into the above suspension at 30°C followed by heating to
80-85°C and stirred at 80-85°C for 8 hrs. Reaction mixture was then cooled to
30°C, poured into ice-water mixture and the suspension was extracted with ethyl acetate (3x200 ml). The combined organic extract was washed with DM water (3 x 150 ml), dried over sodium sulfate and concentrated under reduced pressure to give semisolid compound (6.0 g, 73%).
Step 4: Preparation of 1-[4-(4-(piperazinyl)phenoxy]-2-(2,4-difluorophenyl)-
1 (R/S)-methyl-3-(1 H-1 ,2,4-triazolyl)- propan-2-ol
Step 3 product (6.0 g) was dissolved in 1 ,4-dioxane (50 ml) followed by the addition of a solution of sodium hydroxide (1.0 g) in water (50 ml). Heated the reaction mixture to reflux, stirred it at reflux for about 5 hrs and concentrated under reduced pressure to give a brown semi-solid residue. This brown semi solid was redissolved in ethyl acetate (200 ml), washed with DM water (2x100 ml), dried over sodium sulphate and concentrated to get a pure brown semi-solid (4.5 g; 81 %).
Step 5: Preparation of [1 R2R/1S2S) 1-{4-[4-(4-chlorophenylureido)-piperaziny]- phenoxy}-2-(2,4- difluorophenyl)-1 -methyl-3-(1 H-1 ,2,4-triazolyl)-propan-2-ol. (Compound No. 77) and
[1 R2R/1 S2S]-1 -{4-[4-(4-chlorophenylureido)-piperazinyl]-phenoxy}-2-(2,4- difluorophenyl)-1-methyl-3-(1 H-1 ,2,4-triazolyl)propane-2-ol. (Compound No. 78).
Dissolved the amine obtained as Step 4 product (Formula VII) (800 mg) in anhydrous acetonitrile (5 ml) followed by the addition of p-chlorophenyl isocyanate (3.44 mg). The reaction mixture so obtained was stirred for 1 hour at room temperature and after the reaction was over, the solvent was evaporated off to give brown semi solid residue which was purified using column chromatography. The two spots observed on TLC were separated by preparative HPLC (Upper spot, 50mg, 30%, compound No. 77; Lower spot, 25mg, 20%, Compound No. 78)
EXAMPLE 8
Preparation of 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM - yl)propyl]-4-{4-[4-(4-chlorophenyluredio)-1-piperazinyI]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone (Compound No. 91)
Dissolved the starting amine of Formula VII (following the method as described in US Patent No. 5,371 ,101) in anhydrous acetonitrile and added p- chlorophenyl isocyanate (1.2 moler equivalent) to it and stirred for 1 hr at 25-
30°C. After completion of the reaction, the solvent was evaporated off to obtain a crude product which was purified using column chromatography.
Assignment of RR/SS was done on the basis of 1HNMR analysis.
An illustrative list of some of the compounds of the invention which were synthesized by one or more of the above described methods is given below along with their ΗNMR data. All ΗNMR spectra were recorded on Brucker AMX 300 NMR machines (300 MHZ) using CDCI3 as a solvent and TMS as an internal standard unless otherwise specified. All values are given in ppm.
Symbols in the examples have the following meanings. Thus, s singlet; d:doublet; triplet; q:quartet; dd: double doublet; m:multiplet; br:broad; J: coupling constant:
Compound No. 1 :
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(4-chlorophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone NMR(CDCI3):- δ 7.96(s, 1 H; Ar-H), 7.72-7.67 (d, 2H; J = 14.7 Hz; Ar-H), 7.60-7.52 (q, 1 H; Ar-H), 7.45-7.42 (d, 2H; J = 9.0 Hz; Ar-H), 7.26-7.23 (d, 2H; J = 9.0 Hz; Ar-H), 7.06-7.03 (d, 2H; J = 9.0 Hz; Ar-H), 6.91-6.88(d, 2H; J = 9.0 Hz; Ar-H), 6.83-6.77(m, 2H; Ar-H), 5.56 (s, 1 H; OH, D2O ex.), 5.12-5.05(q, 1 H; -CH.CH3), 5.03-4.98 (d, 1 H; J = 15.0 Hz; triazole-CH2), 4.38-4.33 (d, 1 H; J = 15.0 Hz; triazole-CH2), 3.39-3.37 (d, 8H; piperazine-CH2-) & 1.31-1.28(d, 3H; J = 7.2 Hz; - CH.CH3)ppm.
Compound No. 2:
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(4-chlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
NMR(CDCI3):- δ 8.09(s, 1 H; Ar-H), 7.68 (s, 1 H; Ar-H), 7.39(s, 1 H; Ar-H), 7.36-7.30 (m, 1 H; Ar-H), 7.26-7.22 (m, 3H; Ar-H), 7.16-7.13 (d, 2H; J = 9.0 Hz; Ar-H), 6.97- 6.94(d, 2H; J = 9.0 Hz; Ar-H), 6.89-6.87(d, 2H; J = 9.0 Hz; Ar-H), 6.77-6.63(m, 2H; Ar-H),6.04(s, 1 H;Ar-H), 5.29 (s, 1 H; OH, D2O ex.), 5.11-5.04(q, 1 H; -CH.CH3), 4.92-4.88 (d, 1 H; J = 15.0 Hz; triazole-CH2), 4.63-4.59 (d, 1 H; J = 15.0 Hz; triazole-CH2), 3.34-3.28 (q, 8H; piperazine-CH2-) & 1.64-1.61 (d, 3H; J = 7.2 Hz; - CH.CH3)ppm.
Compound No. 3: 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(2,4-dinitrophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
NMR(CDCI3):- δ 8.81-8.80(d, 1 H; Ar-H), 8.40-8.36(dd, 1 H; Ar-H),8.03(s,1 H;Ar-H), 7.79-7.75 (d, 2H; Ar-H), 7.65-7.62(q, 1 H; Ar-H), 7.54-7.51 (d, 2H; Ar-H), 7.25- 7.22 (d, 1 H; Ar-H), 7.09-7.07 (d, 2H; J = 9.0 Hz; Ar-H), 6.91-6.85(m, 2H; Ar-H),
5.60 (s, 1 H; OH, D2O ex.), 5.17-5.05(qd, 2H; -CH.CH3& triazole-CH2), 4.46-4.41 (d, 1 H; J = 15.0 Hz; triazole-CH2), 3.54-3.53 (d, 8H; piperazine-CH2-) & 1.37- 1.35(d, 3H; J = 7.2 Hz; -CH.CH3)ppm. Compound No. 4:
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-l - yl) propyl}-4-{4-[4-(2,4-dinitrophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone NMR(CDCl3):- δ 8.73-8.72(d, 1 H; Ar-H), 8.32-8.28(dd, 1 H; Ar-H),8.08(s, 1 H; Ar-
H),7.68 (s, 1 H; Ar-H), 7.41 (s, 1 H; Ar-H), 7.35-7.32 (m, 1 H; Ar-H), 7.18-7.13 (m, 3H; Ar-H), 6.76-6.74(d, 2H; J = 9.0 Hz; Ar-H), 6.73-6.63(m, 2H; Ar-H), 5.99 (s, 1 H; OH, D20 ex.), 5.09-5.07(q, 1 H; -CH.CH3), 4.93-4.88 (d, 1 H; J = 15.0 Hz; triazole-CH2), 4.64-4.59 (d, 1 H; J = 15.0 Hz; triazole-CH2), 3.46-3.39 (q, 8H;piperazine-CH2-) & 1.64-1.61 (d, 3H; J = 7.2 Hz; -CH.CH3) ppm.
Compound No. 5:
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-[4-(1 -phenylpiperazinyl)phenyl]-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 7.96(s, 1 H; Ar-H), 7.72-7.67 (d, 2H; J = 13.5 Hz; Ar-H), 7.60-7.52
(q, 1 H; Ar-H), 7.44-7.41 (d, 2H; J = 9.0 Hz; Ar-H), 7.33-7.26 (m, 3H; Ar-H), 7.07- 6.97 (m, 4H; Ar-H), 6.93-6.88(m,1 H; Ar-H), 6.84-6.77(m, 2H; Ar-H), 5.56 (s, 1 H; OH, D2O ex.), 5.12-4.98(qd, 2H; -CH.CH3triazole-CH2), 4.38-4.33 (d, 1 H; J = 15.0 Hz; triazole-CH2), 3.38-3.37 (d, 8H; piperazine-CH2-) & 1.30-1.28(d, 3H; J = 6.9 Hz; -CH.CH3) ppm.
Compound No. 6:
2-{[1 R2S/1S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(1-phenylpiperazinyl) phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.09 (s, 1 H; Ar-H), 7.68 (s, 1 H; Ar-H), 7.39 (s, 1 H; Ar-H), 7.36-
7.26 (m, 3H; Ar-H), 7.15-7.12 (d, 2H; J = 9.0 Hz; Ar-H), 6.97-6.87 (m, 5H; Ar-H), 6.77-6.64 (m, 2H; Ar-H), 6.05 (s, 1 H; OH, D2O ex.), 5.09-5.07 (q, 2H; -CH.CH3 triazole-CH2), 4.91-4.87 (d, 1 H; J = 15.0 Hz; triazole-CH2), 4.63-4.58 (d, 1 H; J ~ 15.0 Hz; triazole-CH2), 3.34 (s, 8H; piperazine-CH2-) & 1.63-1.61 (d, 3H; J = 6.9 Hz; -CH.CH3) ppm. Compound No. 7:
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-l - yl) propyl}-4-{4-[4-(3,4-dichlorophenyl)-1-piperzinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone NMR(CDC!3):- δ 7.96(s, 1 H; Ar-H), 7.71-7.67 (d, 2H; J = 13.5 Hz; Ar-H), 7.61-7.52
(q, 1 H; Ar-H), 7.45-7.42 (d, 2H; J = 9.0 Hz; Ar-H), 7.33-7.30 (d, 1 H; J = 8.7 Hz; Ar-H), 7.06-7.01 (m, 3H; Ar-H), 6.84-6.77(m,3H; Ar-H), 5.56 (s, 1 H; OH, D2O ex.), 5.12-5.05(q, 1 H; -CH.CH3), 5.03-4.98 (d, 1H; J = 15.0 Hz; triazole-CH2), 4.38- 4.34 (d, 1 H; J = 15.0 Hz; triazole-CH2), 3.39-3.37 (d, 8H; piperazine-CH2-) & 1.30- 1.28(d, 3H; J = 7.2 Hz; -CH.CH3)ppm.
Compound No. 8:
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(3,4-dichlorophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
NMR(CDCI3):- δ 8.08 (s, 1 H; Ar-H), 7.67 (s, 1 H; Ar-H), 7.39-7.25 (m, 3H; Ar-H), 7.15-7.12 (d, 2H; J = 9.0 Hz; Ar-H), 6.99-6.93 (m, 3H; Ar-H), 6.79-6.65 (m, 3H; Ar-H), 6.01 (s, 1 H; OH, D2O ex.), 5.10-5.05 (q, 1 H; -CH.CH3), 4.91-4.87 (d, 1 H; J = 15.0 Hz; triazole-CH2), 4.62-4.58 (d, 1 H; J = 15.0 Hz; triazole-CH2), 3.31 (s, 8H; piperazine-CH2-) & 1.63-1.60 (d, 3H; J = 7.2 Hz; -CH.CH3) ppm.
Compound No. 9:
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(3-trifluoromethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone NMR(CDCl3):- 7.99(s, 1 H; Ar-H), 7.74-7.70 (d, 2H; J = 14.7 Hz; Ar-
H), 7.62-7.54 (q, 1 H; Ar-H), 7.48-7.39 (m, 3H; Ar-H), 7.19-7.07 (m, 5H; Ar-H), 6.85-6.79(m, 2H; Ar-H), 5.59 (s, 1 H; OH, D2O ex.), 5.15-5.01 (qd, 1 H; -CH.CH3 & triazole-CH2), 4.40-4.35 (d, 1 H; J = 15.0 Hz; triazole-CH2), 3.43 (s, 8H; piperazine-CH2-) & 1.32-1.30(d, 3H; J = 7.2 Hz; -CH.CH3) ppm. Compound No. 10:
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(3-trifluoromethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone NMR(CDCI3):- δ 8.12(s, 1 H; Ar-H), 7.71 (s, 1 H; Ar-H), 7.43-7.32 (m, 3H; Ar-H), 7.15-7.11 (m, 5H; Ar-H), 7.00-6.97(d, 2H;Ar-H), 6.78-6.66 (m, 2H;
Ar-H), 6.06 (s, 1 H; OH, D2O ex.), 5.13-5.07(q, 1 H; -CH.CH3), 4.95-4.90 (d, 1 H; J = 15.0 Hz; triazole-CH2),4.65-4.61 (d, 1 H; J = 15.0 Hz; triazole-CH2), 3.39 (s, 8H; piperazine-CH2-) & 1.66-1.64(d, 3H; J = 9.6 Hz; -CH.CH3) ppm.
Compound No. 11 :
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(4-fluorophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone NMR(CDCl3) 7.96.09 (s, 1 H; Ar-H), 7.72 (s, 1 H; Ar-H), 7.67 (s, 1 H;
Ar-H), 7.55-7.57 (m, 1 H; Ar-H), 7.41-7.44 (d, 2H; Ar-H), 6.77-7.07 (m, 8H; Ar-H), 5.57 (S, 1 H; OH, D2O ex.), 5.10-5.17 (q, 1 H; J = 7 Hz; -CH), 4.98-5.03 (d, 1 H; J
= 14.7 Hz, -CH), 4.33-4.37 (d, 1 H; J = 14.7-Hz; triazoIe-CH2), 3.38-3.40 (m, 4H; 2 x -CH2), 3.25-3.29 (m, 4H; 2 x CH2-) & 1.28 (d, J = 7 Hz; 3H; CH3) ppm.
Compound No. 12: 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
NMR(CDCI3):- δ 8.09 (s, 1 H; Ar-H), 7.68 (s, 1 H; Ar-H), 6.60-7.40 (m, 12H; Ar-H),
6.02 (S, 1 H; OH, D2O ex.), 5.04-5.11 (q, 1 H; J = 7 Hz; -CH), 4.87-4.92 (d, 1 H; J = 14.7 Hz, -CH), 4.58-4.63 (d, 1 H; J = 14.7 Hz; triazole-CH2), 3.33-3.44 (m, 4H; 2 x
-CH2), 3.23-3.25 (m, 4H; 2 x CH2-) & 1.28 (d, J = 7 Hz; 3H; CH3) ppm.
Compound No. 13:
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone NMR(CDCI3):- δ 7.97 (s, 1 H; Ar-H), 7.74 (s, 1 H; Ar-H), 7.67 (s, 1 H; Ar-H), 7.60- 7.51 (m, 1 H; Ar-H), 7.44-7.41 (d, 2H; Ar-H), 7.28 (s, 1 H; Ar-H), 7.07-7.04 (d, 2H; Ar-H),6.98-6.95 (m, 2H; Ar-H), 6.89-6.86 (m, 2H; Ar-H),6.82-6.77 (m, 2H; Ar- H),5.59 (S, 1 H; OH, D2O ex.), 5.10-4.99 (q, 1 H; J = 7 Hz; -CH), 4.37-4.33 (d, 1 H; J = 14.7 Hz, -CH), 3.79(s, 3H; OCH3), 3.41-3.38 (t, 4H; 2 x -CH2), 3.25-3.22 (t,
4H; 2 x CH2-) & 1.30-1.25 (d, J = 7 Hz; 3H; CH3) ppm.
Compound No. 15:
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(3-chloro-4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-
1 ,2,4-triazolone NMR(CDCl3):- ( s, 1 H; Ar-H), 7.73-7.69(d, 2H; Ar-H), 7.62-
7.53(m, 1 H; Ar-H), 7.46-7.43(d, 2H; Ar-H), 7.10-7.05(t, 3H; Ar-H),7.00-6.98 (m, 1 H; Ar-H), 6.85-6.79(m, 3H; Ar-H),5.57 (s, 1 H; OH, D2O ex.), 5.14-5.00 (m, 2H; J
= 7 Hz; -CH), 4.39-4.35 (d, 1 H; J = 14.7 Hz, -CH), 3.40-3.38 (d, 4H; 2 x -CH2), 3.30-3.29 (d, 4H; 2 x CH2-) & 1.32-1.30(d, J = 7 Hz; 3H; CH3) ppm.
Compound No. 16:
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(3-chloro-4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone NMR(CDCI3) δ8.02(s, 1 H; Ar-H), 7.61 (s, 1 H; Ar-H), 7.37 (s, 1 H;
Ar-H), 7.33-7.23 (m, 1 H; Ar-H), 7.09-7.06(d, 2H; Ar-H), 6.98-6. 956(t, 1 H; Ar-H), 6.90-6. 87(d, 3H; Ar-H),6.76-6.57 (m, 3H; Ar-H),5.96 (s, 1 H; OH, D2O ex.), 5.05- 4.98(q, 1 H; J = 7 Hz; -CH-CH3), 4.87-4.81 (d, 1 H; J = 14.7 Hz, -CH), 4.57-4.52 (d, 1 H; J = 14.7 Hz, -CH), 3.27-3.25 (t, 4H; 2 x -CH2), 3.19-3.18 (t, 4H; 2 x CH2-) & 1.57-1.55(d, J = 7 Hz; 3H; CH3)
Compound No. 17:
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(3-chloro-4-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone NMR(CDCl3):- 7.98 (s, 1 H; Ar-H), 7.74-7.69(d, 2H; Ar-H), 7.62-
7.53(q, 1 H; Ar-H), 7.46-7.43(d, 2H; Ar-H), 7.16-7.13(d, 1 H; Ar-H), 7.08-7.05(d, 2H; Ar-H), 6.98-7.97 (m, 1 H; Ar-H),6.86-7.98 (m, 3H; Ar-H), 5.59 (s, 1 H; OH, D2O ex.), 5.14-5.00 (m, 2H; J = 7 Hz; -CH), 4.39-4.35 (d, 1 H; J = 14.7 Hz, -CH), 3.40- 3.38 (d, 4H; 2 x -CH2), 3.33-3.32 (d, 4H; 2 x CH2-) , 2.31 (s, 3H; Ar-CH3) & 1.32-
1.29 (d, J = 7 Hz; 3H; CH3) ppm.
Compound No. 19:
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazol-1 - yl) propyl}-4-{4-[4-(2,4-dimethylphenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone NMR(CDCI3):- δ 7.48 (s, 1 H; Ar-H), 7.74 (s, 1 H; Ar-H), 7.69 (s, 1 H; Ar-H), 7.53-
7.61 (m, 1 H; Ar-H), 7.42-7.45 (m, 2H; Ar-H), 6.47-7.08 (m, 5H; Ar-H), 6.78-6.85 (m, 2H, Ar-H), 5.60 (s, 1 H; OH, D2O ex.), 5.07-5.14 (q, 1 H; J = 7 Hz; -CH), 5.00- 5.05 (d, 1 H; J = 14 Hz, -CH), 4.34-4.39 (d, 1 H; J = 14 Hz; triazole-CH2), 3.37- 3.40 (m, 4H; 2 x -CH2), 3.05-3.09 (m, 4H; 2 x CH2-), 2.33 (s, 3H, CH3), 2.30 (s, 3H, CH3) & 1.29-1.32 (d, J = 7 Hz; 3H; CH3) ppm
Compound No. 20:
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(2,4-dimethylphenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone
NMR(CDCI3):- δ 8.08 (s, 1H; Ar-H), 7.67 (s, 1H; Ar-H), 7.31-7.39 (m, 2H; Ar-H), 6.94-7.14 (m, 7H; Ar-H), 6.63-6.76 (m, 2H, Ar-H), 6.06 (s, 1 H; OH, D2O ex.), 5.04- 5.11 (q, 1 H; J = 7 Hz; -CH), 4.87-4.92 (d, 1 H; J = 15 Hz, -CH), 4.58-4.63 (d, 1 H; J = 15 Hz; triazole-CH2), 3.31-3.34 (m, 4H; 2 x -CH2), 3.02-3.03 (m, 4H; 2 x CH2- ), 2.29 (s, 3H, -CH3), 2.28 (s, 3H, CH3) & 1.61 -1.63 (d, J = 7 Hz; 3H; CH3) ppm
Compound No. 21 :
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(5-chloro-2-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone NMR(CDCI3):- δ8.03(s, 1 H; Ar-H), 7.78-7.73(d, 2H; Ar-H), 7.62-
7.60(q, 1 H; Ar-H), 7.50-7.47(d, 2H; Ar-H), 7.19-7.03(m, 5H; Ar-H), 6.89-6.82 (m, 2H; Ar-H), 5.58 (s, 1 H; OH, D2O ex.), 5.16-5.04 (m, 2H; J = 7 Hz; -CH), 4.43-4.39 (d, 1 H; J = 14.7 Hz, -CH), 3.45-3.41 (d, 4H;2 x-CH2), 3.13-3.10 (d, 4H; 2 x CH2-), 2.35(s, 3H; Ar-CH3) & 1.36-1.33 (d, J = 7 Hz; 3H; CH3) ppm.
Compound No. 22:
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4-triazoM - yl) propyl}-4-{4-[4-(5-chloro-2-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone NMR(CDCI3):- δ8.15(s, 1 H; Ar-H), 7.74 (s, 1 H; Ar-H), 7.46- 7.39(m, 1 H; Ar-H), 7.31 (s, 1 H; Ar-H), 7.21-7.15(t, 3H; Ar-H), 7.05-6.99(m, 4H; Ar- H), 6.79-7.72 (m, 2H; Ar-H), 6.12 (s, 1 H; OH, D2O ex.), 5.15-5.13 (q, 1 H; J = 7
Hz; -CH-CH3), 4.98-4.93 (d, 1 H; J = 14.7 Hz, -CH), 4.69-4.64 (d, 1 H; J = 14.7 Hz, -CH), 3.40-3.37 (t, 4H; 2 x -CH2), 3.10-3.07 (d, 4H; 2 x CH2-), 2.33(s, 3H; Ar-CH3) & 1.69-1.67 (d, J = 7 Hz; 3H; CH3) ppm.
Compound No. 35:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2- methoxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-1 ,2,4-triazolone NMR(CDCI3):- δ 8.16 (s, 1 H; Ar-H), 7.81 (s, 1 H; Ar-H), 7.60-7.57 (m, 1 H; Ar-H), 7.02-6.79 (m, 9H; Ar-H), 6.10 (s, 1 H; OH; D2O ex.), 4.70 (s, 2H; triazolone-CH2), 4.55-4.50 (d, 1 H; J = 14.7 Hz; triazole-CH2), 4.18-4.13 (d,1 H; J = 15.0 Hz; triazole-CH2), 3.89 (s, 3H; o-OCH3-), 3.41 (s, 4H; piperazine-CH2-),3.21 (s, 4H; piperazine-CH2-) & 2.04(s, 3H; triazolone-CH3) ppm.
Compound No. 36: 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-1 ,2,4-triazolone NMR(CDCI3-DMSO-d6):- δ 8.19 (s, 1 H; Ar-H), 7.77 (s, 1 H; Ar-H), 7.60-7.52 (m, 1 H; Ar-H), 7.42 (s, 1 H; Ar-H), 7.32-7.30 (d, 1 H; J = 8.7 Hz; Ar-H), 7.08-7.29 (m, 9H; Ar-H), 6.86-6.79 (m, 2H; Ar-H), 6.09 (s, 1 H; OH, D2O ex.), 4.72 (s, 2H; triazolone-CH2), 4.50-4.60 (d, 1H; J =14.7 Hz;triazole-CH2), 4.19-4.15 (d, 1 H; J = 14.7 Hz; triazole-CH2), 3.39-3.33 (br, 4H;piperazine-CH2-), 3.26 (s, 4H; piperazine-CH2-) & 2.04 (s, 3H; triazolne-CH3) ppm.
Compound No. 37: 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -y|)propyl]-4-{4-[4-(3,4- dichlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.16 (s, 1 H; Ar-H), 7.83 (s, 1 H; Ar-H), 7.59-7.56 (m, 1 H; Ar-H),
7.49 (s, 1 H; Ar-H), 7.32-7.26 (m, 4H; Ar-H), 6.99-6.97 (d, 3H; Ar-H), 6.85-6.76 (m, 3H; Ar-H), 4.70 (s, 2H; triazolone-CH2), 4.63-4.58 (d, 1 H; J = 14.7 Hz; triazole- CH2), 4.21-4.16 (d, 1 H; J = 14.7 Hz; triazole-CH2), & 3.33 (s, 8H; piperazine-
CH2-) ppm.
Compound No. 38:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2,4- diaminophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
NMR(CDCI3):- δ 8.19 (s, 1 H; Ar-H), 7.85 (s, 1 H; Ar-H), 7.63-7.55 (m, 1 H; Ar-H), 7.51 (s, 1 H; Ar-H), 7.28-7.25 (d, 3H; Ar-H), 7.01-6.98 (d, 2H; Ar-H), 6.89-6.80 (m, 3H; Ar-H), 6.15-6.10 (m,br, 2H; Ar-H), 4.72 (s, 2H; triazolone-CH2), 4.65-4.60 (d, 1 H; J = 15.0 Hz; triazole-CH2), 4.23-4.18 (d, 1 H; J = 15.0 Hz; triazole-CH2), 3.34 (s, br, 4H; piperazine-CH-r, , & 3.02-3.00 (d, 4H; piperazine-CH2-)ppm.
Compound No. 39:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.18 (s, 1 H; Ar-H), 7.85 (s, 1 H; Ar-H), 7.64-7.55 (q, 1 H; Ar-H),
7.50 (s, 1 H; Ar-H), 7.29-7.27 (t, 3H; Ar-H), 7.14-7.11 (d, 2H; Ar-H), 7.03-6.99 (d, 2H; Ar-H), 6.93-6.80 (m, 4H; Ar-H), 5.95 (s, 1 H; OH, D2O ex.), 4.72 (s, 2H; triazolone-CH2), 4.66-4.61 (d, 1 H; J = 15.0 Hz; triazole-CH2), 4.23-4.17 (d, 1 H; J = 14.7 Hz; triazole-CH2), 3.38-3.36 (d, 4H; piperazine-CH2-), 3.31-3.29(d, 4H; piperazine-CH2-) & 2.31 (s, 3H; triazolne-CH3) ppm. Compound No. 40:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1-yl)propyl]-4-{4-[4-(2,4- dinitrophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.74-8.73 (d, 1 H; Ar-H), 8.33-8.29 (m, 1 H; Ar-H), 8.17 (s, 1 H; Ar- H), 7.82 (s, 1 H; Ar-H), 7.60-7.53 (m, 2H; Ar-H), 7.32-7.29 (d, 3H; Ar-H), 7.19-7.16 (d, 1 H; Ar-H), 6.98-6.95 (d, 2H; Ar-H), 6.85-6.79 (m, 2H; Ar-H), 5.90 (s, 1 H; OH, D2O ex.), 4.72 (s, 2H; triazolone-CH2), 4.62-4.57 (d, 1 H; J = 14.7 Hz; triazole- CH2), 4.22-4.18 (d, 1 H; J = 14.7 Hz; triazole-CH2), 3.46-3.43(d, 8H; piperazine- CH2-) ppm
Compound No. 41 :
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- methoxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.19 (s, 1 H; Ar-H), 7.86 (s, 1 H; Ar-H), 7.65-7.57 (q, 1H; Ar-H), 7.51 (s, 1H; Ar-H), 7.31-7.28 (m, 2H; Ar-H), 7.04-6.81 (m, 8H; Ar-H), 5.96 (s, 1 H;
OH, D2O ex.), 4.73 (s, 2H; triazolone-CH2), 4.66-4.61 (d, 1 H; J = 15.0 Hz; triazole-CH2), 4.24-4.19 (d, 1 H; J = 15.0 Hz; triazole-CH2), 3.81 (s, 3H, -OCH3), 3.40-3.37 (d, 4H; J piperazine-CH2-), & 3.26-3.23 (d, 4H; piperazine-CH2-) ppm.
Compound No. 42:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-{4-[4-(2- methoxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.19 (s, 1 H; Ar-H), 7.85 (s, 1 H; Ar-H), 7.64-7.55 (q, 1 H; Ar-H), 7.50 (s, 1 H; Ar-H), 7.29-7.26 (t, 2H, Ar-H), 7.09-6.80 (m, 8H;Ar-H), 4.72 (s, 2H; triazolone-CH2), 4.66-4.61 (d, 1 H; J = 15.0 Hz; triazole-CH2), 4.23-4.18 (d, 1 H; J
= 14.7 Hz; triazole-CH2), 3.91 (s, 3H, -OCH3), 3.43-3.39 (t, 4H; piperazine-CH2-), & 3.25-3.22 (t, 4H; piperazine-CH2~) ppm.
Compound No. 43: 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.17 (s, 1 H; Ar-H), 7.84 (s, 1 H; Ar-H), 7.59-7.57 (q, 1 H; Ar-H), 7.49 (s, 1 H; Ar-H), 7.29-7.26 (t, 2H; Ar-H), 7.03-6.79 (s, 8H; Ar-H), 5.93 (s, 1 H OH, D2O ex.), 4.71 (s, 2H; triazolone-CH2), 4.64-4.59 (d, 1 H; J = 14.7 Hz triazole-CH2), 4.21-4.17 (d, 1 H; J = 14.7 Hz; triazole-CH2), 3.38-3.34 (t, 4H piperazine-CH2-), & 3.27-3.24 (t, 4H; piperazine-CH2-) ppm.
Compound No. 44:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- hydroxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.86 (s, 1 H; Ar-H), 8.32-8.27 (d, 2H; Ar-H), 7.72 (s, 1 H; Ar-H),
7.44-7.41 (d, 2H; Ar-H), 7.33-7.30 (q, 1H; Ar-H), 7.18-7.14 (t, 1H; Ar-H), 7.10- 7.07 (d, 2H; Ar-H), 6.94-6.84 (m, 3H; Ar-H), 6.69-6.66 (d, 2H; Ar-H), 6.19 (s, 1 H; OH, D2O ex), 4.83-4.77 (d, 1 H; J = 14.4 Hz; triazole-CH2), 4.66-4.62 (d, 1 H; J = 14.4 Hz; triazole-CH2), 4.20 (s, 2H; triazolone-CH2), 3.35-3.32 (merging with DMSO-d6 signal)(s, 4H; piperazine-CH2-), & 3.11-3.09(d, 4H; piperazine-CH2-) ppm.
Compound No. 45:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yI)propyl]-4-[4-[1 - phenylpiperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.19(s, 1 H;
Ar-H), 7.85 (s, 1 H; Ar-H), 7.64-7.56 (s, 1 H; Ar-H), 7.50 (s, 1 H; Ar-H), 7.35-7.27
(m, 5H; Ar-H), 7.03-6.80 (m, 7H; Ar-H), 5.95 (s, 1 H; OH, D2O ex.), 4.72 (s, 2H; triazolone-CH2), 4.66-4.61 (d, 1 H; J = 14.7 Hz; triazole-CH2), 4.23-4.18 (d, 1 H; J
= 14.7 Hz; triazole-CH2), & 3.37(s, 8H; piperazine-CH2-) ppm.
Compound No. 46:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-{4-[4-(4- < chlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-1 ,2,4-triazolone
NMR(CDCI3):-δ8.17 (s, 1 H;Ar-H), 7.81 (s, 1 H;Ar-H), 7.58-7.55 (m, 1 H;Ar-H), 7.32- 7.26 (m, 2H;Ar-H), 7.06-6.78 (m, 9H;Ar-H), 6.06 (s, 1 H; OH, D2O ex.), 4.70 (s,
2H; triazolone-CH2), 4.54-4.49 (d, 1 H; J = 14.7 Hz; triazole-CH2), 4.19-4.14 (d, 1 H; J = 14.7 Hz; triazole-CH2), 3.37-3.33 (t, 8H; piperazine-CH2-), & 2.03 (s, 3H; triazolone-CH3) ppm.
Compound No. 47: 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -y|)propyl]-4-{4-[4-(4- chlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.17 (s, 1 H; Ar-H), 7.83 (s, 1 H; Ar-H), 7.62-7.54 (m, 1 H; Ar-H), 7.50 (s, 1 H; Ar-H), 7.29-7.23 (m, 4H; Ar-H), 7.01-6.98 (d, 2H; Ar-H), 6.91-6.79 (m, 8H; Ar-H), 5.96 (s, 1 H; OH, D2O ex.), 4.72 (s, 2H; triazolone-CH2), 4.63-4.59 (d, 1 H; J = 14.7 Hz; triazole-CH2), & 4.22-4.17 (d, 1 H; J = .7 Hz; triazole-CH2), &
3.37-3.30 (q, 8H; piperazine-CH2-) ppm. Compound No. 48:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(5- chloro-2-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.28 (s, 1 H; Ar-H), 7.90 (s, 1 H; Ar-H), 7.66-7.58 (m, 1H; Ar-H),
7.53 (s, 1 H; Ar-H), 7.32-7.29 (t, 2H; Ar-H), 7.29-7.26(d, 2H; Ar-H), 7.16-7.14 (d, 1 H; Ar-H), 7.04-7.02(d, 4H, Ar-H), 6.89-6.82(m, 2H, Ar-H),5.96(br, 1 H; OH, D2O ex.), 4.74 (s, 2H; triazolone-CH2), 4.67-4.62 (d, 1 H; J = 14.7 Hz; triazole-CH2), & 4.26-4.20 (d, 1 H; J = 14.7 Hz; triazole-CH2), 3.40-3.33(m, 4H; piperazine-CH2-) , 3.10-3.07 (m, 4H; piperazine-CH2-) ppm.
Compound No. 49:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(3- chloro-4-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCl3):- δ 8.20 (s, 1 H; Ar-H), 7.87 (s, 1 H; Ar-H), 7.65-7.58 (q, 1 H; Ar-H),
7.52 (s, 1 H; Ar-H), 7.31-7.29 (d, 2H; Ar-H), 7.16-7.14(d, 2H; Ar-H),7.04-6.98 (m,
3H; Ar-H), 6.88-6.80 (m, 3H; Ar-H), 5.96(s, 1 H; OH, D2O ex.), 4.74 (s, 2H; triazolone-CH2), 4.67-4.62 (d, 1 H; J = 14.7 Hz; triazole-CH2), & 4.24-4.17 (d, 1 H;
J = 14.7 Hz; triazole-CH2), & 3.3-3.33 (m, 8H; piperazine-CH2-) ppm. Compound No. 50:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -y|)propyl]-4-{4-[4-(2,4- dichlorophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCl3):-
8.19 (s, 1 H; Ar-H), 7.86 (s, 1 H; Ar-H), 7.65-7.56 (m, 1 H; Ar-H), 7.51 (s, 1 H; Ar- H), 7.43-7.42(d, 1 H; Ar-H),7.31-7.23 (m, 3H; Ar-H), 7.03-7.01 (d, 3H; Ar-H), 6.88- 6.81 (m, 2H; Ar-H), 5.93 (s, 1 H; OH, D2O ex.), 4.73 (s, 2H; triazolone-CH2), 4.66-
4.61 (d, 1 H; J = 14.7 Hz; triazole-CH2), & 4.24-4.19 (d, 1 H; J = 14.7 Hz; triazole-
CH2), 3.42-3.39 (m, 4H; piperazine-CH2-) , 3.22-3.18 (m, 4H; piperazine-CH2-) ppm.
Compound No. 51 :
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(3- trifluoromethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.16 (s, 1 H; Ar-H), 7.83 (s, 1 H; Ar-H), 7.62-7.57 (q, 1 H; Ar-H), 7.49 (s, 1 H; Ar-H), 7.40-7.35 (t, 1 H; Ar-H), 7.29-7.26(d, 2H; Ar-H), 7.15-7.09(m,
3H; Ar-H),7.01-6.98 (d, 2H; Ar-H), 6.84-6.78 (m, 2H; Ar-H), 5.90(s, 1 H; OH, D20 ex.), 4.70 (s, 2H; triazolone-CH2), 4.63-4.58 (d, 1 H; J = 14.7 Hz; triazole-CH2), & 4.21-4.16 (d, 1H; J = 14.7 Hz; triazole-CH2), & 3.37 (s, 8H; piperazine-CH2-) ppm.
Compound No. 52:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2,4- difluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCl3):-
8.16 (s, 1 H; Ar-H), 7.83 (s, 1 H; Ar-H), 7.62-6.78 (m, 11 H; Ar-H), 5.90 (s, 1 H, OH), 4.70 (s, 2H; triazolone-CH2), 4.63 (d, 1 H; J - 14.9 Hz; triazole-CH2-), 4.19 (d, 1 H; J = 14.9 Hz; triazole-CH2-), 3.35 (bm, 4H; piperazine-CH2), 3.16 (bm, 4H; piperazine -CH2) ppm
Compound No. 53:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(3- chloro-4-fluorophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
NMR(CDCI3):- 8.17(s, 1 H; Ar-H), 7.84(s, 1 H; Ar-H), 7.62-7.54 (m, 1 H; Ar-H), 7.49 (s, 1 H; Ar-H), 7.29-7.26 (m, 2H; Ar-H), 7.08-6.95 (m, 4H; Ar-H),6.83-6.98(m, 3H; Ar-H), 5.90 (s, 1 H; OH, D2O ex.), 4.71 (s, 2H; triazolone-CH2), 4.63-4.59 (d,
1 H; J = 14.8 Hz; triazole-CH2), 4.21-4.16 (d, 1 H; J = 14.8 Hz; triazole-CH2),
3.35-3.34 (d, 4H; 2 x piperazine-CH2-) & 3.27-3.26 (d, 4H; 2 x piperazine-CH2-) ppm.
Compound No. 54:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2,4- dimethylphenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCl3):- 8.16 (s, 1 H; Ar-H), 7.82 (s, 1 H; Ar-H), 7.59-7.57 (m, 1 H; Ar-H), 7.48 (s, 1 H; Ar-
H), 7.24-7.27 (m, 3H; Ar-H), 7.02-6.78 (m, 7H; Ar-H), 5.93 (s, 1 H; OH, D2O ex.),
4.63-4.70 (s, 2H; triazolone-CH2), 4.47-4.58 (d, 1H; J = 15 Hz; triazole-CH2),
4.21-4.16 (d, 1 H; J = 15 Hz; triazole-CH2), 3.35-3.32 (m, 4H; 2 x piperazine-CH2-
) , 3.04-3.01 (m, 4H; 2 x piperazine-CH2-) 2.30 (s, 3H; CH3) & 2.28 (s, 3H, CH3) ppm.
Compound No. 57:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-{4-[4-(3- chlorophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCl3):- 8.16 (s, 1 H; Ar-H), 7.83 (s, 1 H; Ar-H), 7.59-7.57 (q, 1 H; Ar-H), 7.49 (s, 1 H; Ar-
H), 7.29-7.26(d, 2H; Ar-H), 7.22-7.17(t, 1 H; Ar-H),7.00-6.97 (d, 2H; Ar-H), 6.92- 6.91 (m, 1 H; Ar-H),6.87-6.78 (m, 4H; Ar-H), 5.90(s, 1 H; OH, D20 ex.), 4.70 (s,
2H; triazolone-CH2), 4.63-4.58 (d, 1 H; J = 14.7 Hz; triazole-CH2), & 4.21-4.16 (d,
1 H; J = 14.7 Hz; triazole-CH2), & 3.34 (s, 8H; piperazine-CH2-) ppm.
Compound No. 58:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1H-1 ,2,4-triazol-1-yl)propyl]-4-{4-[4-(2- chloro-4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.18(s, 1 H; Ar-H), 7.84(s, 1 H; Ar-H), 7.59-7.57 (m, 1 H; Ar-H), 7.49 (s, 1 H; Ar-H), 7.29-6.79 (m, 9H; Ar-H), 5.92 (s, 1 H; OH, D20 ex.), 4.71 (s,
2H; triazolone-CH2), 4.64-4.59 (d, 1 H; J = 14.8 Hz; triazole-CH2), 4.22-4.17 (d, 1 H; J = 14.8 Hz; triazole-CH2), 3.38-3.35 (t, 4H; 2 x piperazine-CH2-) & 3.23-3.20 (t, 4H; 2 x piperazine-CH2-) ppm.
Compound No. 59:
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -y|)propyl]-4-{4-[4-(2- methoxy-5-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone NMR(CDCI3):- δ 8.19(s, 1 H; Ar-H), 7.85(s, 1 H; Ar-H), 7.60-7.57 (m, 1 H; Ar-H), 7.50 (s, 1 H; Ar-H), 7.29-7.26 (m, 3H; Ar-H),7.02-6.99 (d, 2H; Ar-H), 6.85-6.78 (m, 3H; Ar-H),6.72-6.68(m, 2H; Ar-H),5.95 (s, 1 H; OH, D2O ex.), 4.72 (s, 2H; triazolone-CH2), 4.65-4.60 (d, 1 H; J = 14.8 Hz; triazole-CH2), 4.22-4.17 (d, 1 H; J = 14.8 Hz; triazole-CH2), 3.87(s,3H;OCH3), 3.41-3.38 (d, 4H; 2 x piperazine-CH2-) & 3.22-3.21 (d, 4H; 2 x piperazine-CH2-) ppm.
PHARMACOLOGICAL ACTIVITY
Compounds of the Formulae IA, IB, II and III as shown herein, and their salts are useful in the curative or prophylactic treatment of fungal infections in animals, including humans. For example, they are useful in treating topical fungal infection in man caused by, among other organisms, species of Candida, Trichophyton, Microsporum or Epidermophyton in mucosal infections caused by C. albicans (e.g., thrush and vaginal candidiasis). They can also be used in the treatment of systemic fungal infections caused by, for example, species of Candida (e.g., Candida albicans), Cryptococcus neoformans or Aspergillus fumigatus.
The compounds of the present invention have been found to have unexpectedly good activity against clinically important Aspergillus species fungi. The in vitro evaluation of the antifungal activity of the compounds can be performed by determining the minimum inhibitory concentration (MIC) which is the concentration of the test compound in Rosewell Park Memorial Institute (RPMI) 1640 liquid medium buffered with (3-[Morpholino]propanesulphonic acid) MOPS to pH7. at which there is significant inhibition of the particular fungi In practice the National Committee for Clinical Laboratory Standard (NCCLS) M27A document for Candida and Cryptococcus and M38P for Aspergillus was used to determine the MIC against yeast and filamentous fungi with suitable modifications for dermatophytes. Two quality control strains were included each time the MIC were determined and readings recorded only when the QC results fell into the
acceptable range. After MIC results had been recorded, 100 μl from each of the
well showing no growth was spread over Sabouraud Dextrose Aαvar (SPA) to determine the minimum fungicidal concentration.
The in vivo evaluation of the compound can be carried out at a series of dose levels by oral or I.V. injection to mice which are inoculated I.V. with the minimum lethal dose of Candida albicans, Cryptococcus neoformans or Aspergillus fumigatus by the tail vein. Activity is based on the survival of a treated group of mice after the death of an untreated group of mice. For Aspergillus and Cryptococcus infections target organs were cultured after treatment to document the number of mice cured of the infection for further assessment of activity.
For human use, the antifungal compounds of the formula and their salts can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they can be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents. They can be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
The solubility of a compound of the Formulae IA, IB, II and III in an aqueous medium may be improved by complexation with a hydroxyalkyl derivative of a cyclodextrin in the preparation of an appropriate pharmaceutical composition.
For oral and parenteral administration to human patients, the daily dosage level of the antifungal compounds of the Formulae IA, IB, II and III and their salts will be from 0.01 to 20 mg/kg (in single or divided doses) when administered by either the oral or parenteral routes. Thus tablets or capsules of the compound will contain from 5 mg to 0.5 gm of active compound for administration one, two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for an individual patient and it will vary with age, weight and response of the particular patient. The above dosages are exemplary of the average case, there can, of course, be individual instances, where higher or lower dosage ranges are required and such are within the scope of this invention. Alternatively, the antifungal compound or Formulae IA, IB, II and III can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder. For example, they can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin, or they can be incorporated, at a concentration between 1 and 10 % into an ointment consisting of a white wax or white soft paraffin base together with such stabilizers and preservatives as may be required.
Cryptococcosis is a leading cause of morbidity and mortality among AIDS patients. In many patients Cryptococcosis is the first indication of AIDS. The incidences of life-threatening cryptococcal infection among patients with AIDS has been estimated to vary from 10 - 30 %. During initial therapy, 10 - 20 % of these patients die and 30 - 60 % patients succumb within 12 months (Powderly WG: Cryptococcus meningitis and AIDS Clin. Infect. Dis. 1993; 17: 837 - 842).
Amphotericin B has changed disseminated cryptococcosis from uniformly fatal infection to curable infection, but since Amphotericin B penetrates the central nervous system poorly, intraventricular injection may have to be administered for successful management of severe cases of Cryptococcal meningitis. Fluconazole has excellent pharmacokinetics in CSF and performs equally well in patients with Cryptococcal meningitis. However, there is a trend towards earlier deaths and longer period before sterilisation of the CSF (NIAID [National Institute of Allergy and Infection Disease] Mycoses study group and AIDS clinical trials group: comparison of Amphotericin B and Fluconazole in the treatment of acute AIDS associated Cryptococcus meningitis (N Engl J Med 1992; 326: 83 - 89).
Invasive aspergillosis has become a leading cause of death, mainly among patients suffering from acute leukaemia or after allogenic bone marrow transfusion and after cytotoxic treatment of these conditions. It also occurs in patients with conditions such as AIDS and chronic granulomatous disease. At present, only Amphotericin B and Itraconazole are available for treatment of aspergillosis. In spite of their activity in vitro, the effect of these drugs in vivo against Aspergillus fumigatus remains low and as a consequence mortality from invasive aspergillosis remains high.
In vitro activity:
Compounds of this invention have potent in vitro activity against a wide range of fungal pathogens tested. They are active against all species of
Candida, Histoplasma capsulatum, Cryptococcus neoformans, dermatophytes, Aspergillus fumigatus and A. flavus. The action on many of these strains, especially against Cryptococcus and Aspergillus is fungicidal in vitro.
Table containing the biological evaluation of these compounds
Figure imgf000078_0001
Figure imgf000079_0001
In vivo activity:
Compounds of this invention have enhanced antifungal activity against the important fungal pathogens of men and animals.
a) Anti Candida activity:
A single oral dose of 12.5 mg / kg bw. (0.25 mg per mouse) is adequate to offer significant protection to mice infected via the tail vein by lethal dose of C. albicans A-26.
Summary of single dose studies with azoles in systemic infection with Candida albicans A-26
Figure imgf000079_0002
b) Anti cryptococcal activity:-
The compounds of this invention cross the blood brain barrier to excert their potent anti cryptococcal activity in the brain. In an animal model where lethal infection (1 million cells of C. neoformans) were injected into the cranium of the animal, oral dosing with 25 mg/kg bw. BID for 8 days reduced the count by 4 logs, causing 99.99 % reduction in the fungal load.
c) Anti Aspergillus activity:-
Doses as low as 6.25 mg / kg bw. significantly increased the survival of mice infected via the tail vein with lethal dose of Aspergillus fumigatus conidia.
d) Anti Dermatophyte activity:-
Single local application of the drug had significant effect on Trichophyton mentagrophyte infection of guinea pig skin.

Claims

AIM :
A compound of Formula IA
Figure imgf000081_0001
FORMULA IA
and its pharmaceutically acceptable salts, enantiomers, diastereomers, N- oxides, prodrugs or metabolites, wherein
X is selected from the group consisting of CH2, CO, CS, SO2 and -N=N-,
R is selected from the group consisting of (1) C1-C4 alkyl which is unsubstituted or substituted with - 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C C4 alkoxy and amino (2) Cι-C alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C C4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
Ri and R2 are each independently selected from the group consisting of (1 ) hydrogen, (2) Cι-C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) C C alkoxy;
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) Cι-C alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl;
R3 is selected from the group consisting of C1-C4 alkyl group, halogen, hydroxy, Cι-C4 alkoxy, nitro, amino, cyano, carboxyl and SO2R' wherein R' is hydrogen, alkyl or aryl ;
Xi, X2, Y1, Y2 and Z are independently selected from the group consisting of halogen, nitro, cyano, amino, sulphonyl, aryl or substituted aryl, C C alkyl, Cι-C4 alkoxy, carboxyl or protected carboxyl.
2. A compound of Formula IB
Figure imgf000082_0001
FORMULA IB and its pharmaceutically acceptable salts, enantiomers, diastereomers, N- oxides, prodrugs or metabolites, wherein
X is selected from the group consisting of CH2, CO, CS, SO2 and -N=N-,
R is selected from the group consisting of (1 ) Cι-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino (2) C C alkoxy, (3) halogen (4) formyl (5) carboxyl (6) Cι-C acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
Ri and R2 are each independently selected from the group consisting of (1) hydrogen, (2) Cι-C alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) Cι-C4 alkoxy;
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) Cι-C alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl; R3 is selected from the group consisting of Cι-C4 alkyl group, halogen, hydroxy, Cι-C4 alkoxy, nitro, amino, cyano, carboxyl and SO2R' wherein R' is hydrogen, alkyl or aryl ;
R is selected from the group consisting of hydrogen, Ci - C4 alkyl group which is unsubstituted or substituted;
B is selected from oxygen and sulphur atoms; and
R5 is selected from the group (1 ) hydrogen, (2) Ci- C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C1-G4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, CrC alkoxy and amino (b) Cι-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) CrC4 acyloxy (g) C1-C4 alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C1-C4 alkyl) which may be substituted with 1-6 substituents selected from (a) Ci - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino, (b) halogen (c) (C C4 alkyl) halo, (d) Cι-C alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoro- methoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetra- fluoropropyl and (m) tetrafluoropropoxyl.
3. A compound of Formula II
Figure imgf000085_0001
FORMULA H
and its pharmaceutically acceptable salts, enantiomers, diastereomers, N- oxides, prodrugs or metabolites, wherein
X is selected from the group consisting of CH2, CO, CS, SO2 and -N=N-,
R is selected from the group consisting of (1) Cι-C alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino (2) C -C alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C-i-C4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
Ri is selected from the group consisting of (1) hydrogen, (2) C1-C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) d-C4 alkoxy;
R4 is selected from the group consisting of hydrogen, C - C4 alkyl group which is unsubstituted or substituted; and
R is selected from the group (1 ) hydrogen, (2) C-i- C alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-G4 alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C -C alkoxy and amino (b) Cι-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) C1-C4 acyloxy (g) Cι-C alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C C alkyl) which may be substituted with 1-6 substituents selected from (a) Ci - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (b) halogen (c) (C C-4 alkyl) halo, (d) C C alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoro- methoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetra- fluoropropyl and (m) tetrafluoropropoxyl; B is selected from oxygen and sulphur atoms; and
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) CrC4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl.
4. A compound of Formula III
Figure imgf000087_0001
FORMULA m
and its pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, prodrugs or metabolites, wherein
R is selected from the group consisting of (1 ) C1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C -C alkoxy and amino (2) C1-C4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C1-C4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl; Ri is selected from the group consisting of (1 ) hydrogen, (2) C1-C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) C-ι-C4 alkoxy;
Rs is selected from the group (1 ) hydrogen, (2) Ci- C alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C C alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C-1-C4 alkoxy and amino (b) C-1-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) Cι-C4 acyloxy (g) Cι-C alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C1-C4 alkyl) which may be substituted with 1-6 substituents selected from (a) Ci - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (b) halogen (c) (C1- C alkyl) halo, (d) Cι-C alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl 0) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetrafluoropropyl and (m) tetrafluoropropoxyl; X is selected from the group consisting of CH2, CO, CS, SO2 and -N=N-;
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) C C4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl; and
B is selected from oxygen and sulphur atoms.
5. A compound is selected from the group consisting of:
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(4-chlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone (Compound No. 1)
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(4-chIorophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone (Compound No. 2)
2-{[1 R2R/1S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2,4-dinitrophenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No. 3)
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2,4-dinitrophenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No. 4)
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-[4-(1-phenylpiperazinyI)phenyl]-3-(2H,4H)-1 ,2,4- triazolone (Compound No. 5)
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(1-phenylpiperazinyl) phenyl}-3-(2H,4H)-1 ,2,4- triazolone (Compound No.
6) 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-1 -yl) propyl}-4-{4-[4-(3,4-dichlorophenyl)-1 -piperzinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
7)
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(3,4-dichlorophenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
8)
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(3-trifluoromethylphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
9)
2-{[1 R2S/1S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1 ,2,4- triazol-1 -yl) propyl}-4-{4-[4-(3-trifluoromethylphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
10)
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(4-fluorophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone (Compound No.
11 )
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)- 1 ,2,4-triazolone (Compound No.
12)
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(4-methoxyphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
13)
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(4-methoxyphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
14)
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(3-chloro-4-fluorophenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
15)
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(3-chloro-4-fluorophenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
16) 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(3-chloro-4-methylphenyl)-1-piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
17)
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(3-chloro-4-methylphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
18)
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2,4-dimethylphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
19)
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2,4-dimethylphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
20)
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(5-chloro-2-methylphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
21 )
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(5-chloro-2-methylphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-1 ,2,4-triazolone (Compound No.
22)
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(3,4-dimethylphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-5-methyl-1 ,2,4-triazolone (Compound No.
23) 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(3,4-dimethylphenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-5-methyl-1 ,2,4-triazolone (Compound No.
24) 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5- methyl-1 ,2,4-triazolone (Compound No.
25)
2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5- methyl-1 ,2,4-triazolone (Compound No.
26) 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2-methoxy-5-fluorophenyl)-1 -piperazinyljphenyl}- 3-(2H,4H)-5-methyl-1 ,2,4-triazolone (Compound No.
27) 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2-methoxy-5-fluorophenyl)-1 -piperazinyljphenyl}- 3-(2H,4H)-5-methyl-1 ,2,4-triazolone (Compound No.
28) 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(3,5-dichlorophenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-5-methyl-1 ,2,4-triazolone (Compound No.
29) 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(3,5-dichlorophenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-5-methyl-1 ,2,4-triazolone (Compound No.
30) 2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2-ethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5- methyl-1 ,2,4-triazolone (Compound No.
31 )
2-{[1 R2S/1S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2-ethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5- methyl-1 ,2,4-triazolone (Compound No.
32)
2-{[1 R2R/1 S2S]-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2,4-dichlorophenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-5-methyl-1 ,2,4-triazolone (Compound No.
33) 2-{[1 R2S/1 S2R]-2-(2,4-Difluorophenyl)-2-hydroxy-1 -methyl-3-(1 H-1 ,2,4- triazol-l -yl) propyl}-4-{4-[4-(2,4-dichlorophenyl)-1 -piperazinyl]phenyl}-3- (2H,4H)-5-methyl-1 ,2,4-triazolone (Compound No.
34) 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-l -yl)propyl]-4-{4-[4-(2- methoxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-1 ,2,4-triazolone (Compound No.
35)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-{4-[4-(4- fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-1 ,2,4-triazolone (Compound No.
36) 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-
(3,4-dichlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 37)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-
(2,4-diaminophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 38)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- methylphenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound
No.
39)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-
(2,4-dinitrophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 40)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-{4-[4-(4- methoxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound
No.
41 )
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2- methoxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound
No.
42)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoI-1 -yl)propyl]-4-{4-[4-(4- fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound
No.
43)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propylj-4-{4-[4-(4- hydroxyphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound
No.
44)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-[4-[1 - phenylpiperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound No.
45)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1-yl)propyl]-4-{4-[4-(4- chlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-5-methyl-1 ,2,4-triazolone
(Compound No. 46) 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- chlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound
No.
47)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(5- chloro-2-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 48)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-{4-[4-(3- chloro-4-methylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 49)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-
(2,4-dichlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 50)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1-yl)propyl]-4-{4-[4-(3- trifluoromethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 51 )
2-[2-(2,4-Difiuorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-
(2,4-difluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 52)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-{4-[4-(3- chloro-4-fluorophenyl)-1-piperazinyI]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 53)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-
(2,4-dimethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 54)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-
(3,4-difluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 55)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-{4-[4-
(3,4-dimethylphenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 56) 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4- (3- chlorophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound
No.
57).
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2- chloro- 4-fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 58)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2- methoxy- 5-fluorophenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 59)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(2- ethylphenyl)-1 -piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound
No.
60).
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-
(3,5-dichlorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 61 )
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-{4-[4-(2- fluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound
No.
62)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-
(1 ,2,3- trifluorophenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone
(Compound No. 63)
3-{4-[4-(p-tolylaminothiocarbonylamino)piperazinyl]phenoxy}-2-(2,4- difluorophenyl)-1-(1 H-1 ,2,4-triazol-1-yl)-propan-2-ol. (Compound No. 64)
3-{4-[4-(isopropylaminothiocarbonylamino)piperazinyl]phenoxy}-2-(2,4- difluorophenyl)-1-(1 H-1 ,2,4-triazoM -yl)-propan-2-ol. (Compound No. 65)
3-{4-[4-(4-chlorophenylureido)piperazinyI]phenoxy}-2-(2,4-difluorophenyl)-1-
(1 H-1 ,2,4-triazoM -yl)-propan-2-ol (Compound No. 66)
3-{4-[4-(4-chlorophenylureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-1-
(1 H-1 ,2,4-triazo -yl)-propan-2-ol. (Compound No. 67)
3-{4-[4-(1 -napthyl thioureido)piperazinyI]phenoxy}-2-(2,4-difluorophenyl)-1 -
(1 H-1 ,2,4-triazoM -yl)-propan-2-ol. (Compound No. 68) 3-{4-[4-(1 -hapthyl thioureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-1 -
(1 H-1 ,2,4-triazoM -yl)-propan-2-ol. (Compound No. 69)
3-{4-[4-(4-trifluoromethylphenyl thioureido)piperazinyl]phenoxy}-2-(2,4- difluorophenyl)-1-(1 H-1 ,2,4-triazoM -yl)-propan-2-ol. (Compound No. 70)
3-{4-[4-(4-methoxyphenylureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-
1-(1 H-1 ,2,4-triazol-1-yl)-propan-2-ol. (Compound No. 71 )
3-{4-[4-(2,4-dichlorophenylureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-
1-(1 H-1 ,2,4-triazoM -yl)-propan-2-ol (Compound No. 72)
3-{4-[4-(4-chlorophenyl-N-ethylureido)-piperazinyl ]-phenoxy)-2-(2,4- difluorophenyl)-1-(1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 73)
3-{4-[4-(4-chlorophenyl-N-ethylureido)-piperazinyl ]-phenoxy)-2-(2,4- difluorophenyl)-1 -(1 H-1 ,2,4-triazolyl)-2-ethoxy-3-propylamine (Compound No.
74)
3-{4-[4-N-(4-Chlorophenyl)-N-(methyIureido)-piperazinyl ]-phenoxy}-2-(2,4- difluorophenyl)-1-(1 H-1 ,2,4-triazolyl)-2-methoxypropane (Compound No. 75)
3-{4-[4-(4-aminophenylureido)piperazinyl]phenoxy}-2-(2,4-difluorophenyl)-1-
(1 H-1 ,2,4-triazoM -yl)-propan-2-ol. (Compound No. 76)
[1 R2R/1 S2S] 1 -{4-[4-(4-chIorophenylureido)-piperazinyl ]-phenoxy}-2-(2,4- difluorophenyl)-1 -methyl -3-(1 H-1 ,2,4-triazolyl)-propan-2-ol (Compound No.
77)
[1 R2S/1S2R] 1-{4-[4-(4-chlorophenylureido)-piperazinyl ]-phenoxy}2-(2,4- difluorophenyl)-1 -methyl -3-(1 H-1 ,2,4-triazolyl)-propan-2-ol (Compound No.
78)
1-{4-[4-(4-Trifluoromethylphenylureido)piperazinyl]phenoxy}-2-(2,4- difluorophenyl)-1-methyl-3-(1 H-1 ,2,4-triazoM -yl)-propan-2-ol (Compound No.
79)
3-{4-[4-(Phenylureido)-piperazinyl ]-phenoxy}-2-(2,4-difluorophenyl)-1 -(1 H-
1 ,2,4-triazol-1-yl)-propan-2-ol(Compound No. 80)
2-(2,4-Difluorophenyl)-3-{4-(thioureidophenyl)N-methyl-N-phenyl}-1 -(1 H-
1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 81 ) 2-(2,4-Difluorophenyl)-3-{4-(isopropylthioureido)N-methyl-N-phenyl}-1 -(1 H- 1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 82) 3-{N-[4-(p-Tolylthioureido)-phenyrj- N-methyl}-2-(2,4-difluorophenyl)-1 -(1 H- 1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 83) 3-{N-[4-(p-Fluorophenylureido)-phenyl]- N-methyl}-2-(2,4-difluorophenyl)-1 - (1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 84) 3-{N-[4-(p-Nitrophenyltureido)-phenyl]- N-methyl}-2-(2,4-difluorophenyl)-1 - (1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 85) 3-{N-[4-(p-Chlorophenylureido)-phenyl]- N-methyl}-2-(2,4-difluorophenyl)-1 - (1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 86) 3-{N-[4-(Carboxymethyl)-phenyltureido)-phenyl]- N-methyl}-2-(2,4- difluorophenyl)-1-(1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 87) 3-{N-[4-(2-Methoxy-2-oxoethyl)-phenyltureido)-phenyl]- N-methyl}-2-(2,4- difluorophenyl)-1-(1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 88) 3-{N-[4-(p-Chlorophenylthiouredo)-phenyltureido)-phenyl]- N-methyl}-2-(2,4- difluorophenyl)-1-(1 H-1 ,2,4-triazolyl)-propan-3-amino-2-ol (Compound No. 89) 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4- (isopropylthiouredio)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound No. 90)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazol-1 -yl)propyl]-4-{4-[4-(4- chlorophenyluredio)-1-piperazinyI]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound No. 91 )
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- chlorophenylthiouredio)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4-triazolone (Compound No. 92)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- (2-methoxy-2-oxoethyl)phenyi)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone (Compound No. 93)
2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- (carboxyethyl)-phenyl)-1-piperazinyl]phenyI}-3-(2H,4H)-1 ,2,4-triazolone (Compound No. 94) 2-[2-(2,4-Difluorophenyl)-2-hydroxy-3-(1 H-1 ,2,4-triazoM -yl)propyl]-4-{4-[4-(4- (2-hydroxyethyl)phenyl)-1-piperazinyl]phenyl}-3-(2H,4H)-1 ,2,4- triazolone(Compound No. 95)
6. A pharmaceutical composition comprising the compound of claim 1 to 5 and a pharmaceutical acceptable carrier.
7. A pharmaceutical composition comprising a pharmaceutically effective amount of compound according to claim 1 to 5 or a physiologically acceptable acid addition salt thereof with a pharmaceutically acceptable carrier for" treating fungal infection.
8. A method of treating or preventing fungal infection in mammals comprising administering to said animal a compound of Formula IA
Figure imgf000098_0001
FORMULA IA
and its pharmaceutically acceptable salts, enantiomers, diastereomers, N- oxides, prodrugs or metabolites, wherein
X is selected from the group consisting of CH2, CO, CS, SO2 and -N=N-, R is selected from the group consisting of (1 ) C-ι-C alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C alkoxy and amino (2) C1-C4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) Cι-C4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
Ri and R2 are each independently selected from the group consisting of (1 ) hydrogen, (2) C C alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) Cι-C4 alkoxy;
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) C1-C4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl;
R3 is selected from the group consisting of C-i-C4 alkyl group, halogen, hydroxy, Cι-C4 alkoxy, nitro, amino, cyano, carboxyl and SO2R' wherein R' is hydrogen, alkyl or aryl; and Xi, X2, Y1, Y2 and Z are independently selected from the group consisting of halogen, nitro, cyano, amino, sulphonyl, aryl or substituted aryl, C1-C-4 alkyl, C-ι-C4 alkoxy, carboxyl or protected carboxyl.
9. A method of treating or preventing fungal infection in an animal comprising administering to said animal a compound of Formula IB
Figure imgf000100_0001
FORMULA IB
and its pharmaceutically acceptable salts, enantiomers, diastereomers, N- oxides, prodrugs or metabolites, wherein
X is selected from the group consisting of CH2, CO, CS, S02 and -N=N-;
R is selected from the group consisting of (1) C1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (2) C1-C4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C1-C4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl; Ri and R2 are each independently selected from the group consisting of (1 ) hydrogen, (2) C1-C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) S02R' wherein R1 is hydrogen, alkyl or aryl and (8) C1-C4 alkoxy;
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) C-ι-C4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl;
R3 is selected from the group consisting of C1-C4 alkyl group, halogen, hydroxy, C1-C4 alkoxy, nitro, amino, cyano, carboxyl and SO2R' wherein R' is hydrogen, alkyl or aryl;
R4 is selected from the group consisting of hydrogen, C-i - C4 alkyl group which is unsubstituted or substituted;
B is selected from oxygen and sulphur atoms; and
R5 is selected from the group (1) hydrogen, (2) C-i- C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C C4 alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) Cι-C alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (b) C-ι-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) C-1-C4 acyloxy (g) C1-C4 alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C1-C4 alkyl) which may be substituted with 1-6 substituents selected from (a) Ci - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (b) halogen (c) (Cι- C-4 alkyl) halo, (d) C1-C4 alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetrafluoropropyl and (m) tetrafluoropropoxyl.
10. A method of treating or preventing fungal infection in an animal comprising administering to said animal a compound of Formula II
Figure imgf000102_0001
FORMULA π
and its pharmaceutically acceptable salts, enantiomers, diastereomers, N- oxides, prodrugs or metabolites, wherein X is selected from the group consisting of CH2, CO, CS, SO2 and -N=N-;
R is selected from the group consisting of (1 ) C C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino (2) Cι-C4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C-i-C acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
Ri is selected from the group consisting of (1) hydrogen, (2) C C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C C alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) C C4 alkoxy;
R is selected from the group consisting of hydrogen, Ci - C4 alkyl group which is unsubstituted or substituted;
Rs is selected from the group (1 ) hydrogen, (2) Ci- C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (b) C1-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) C1-C4 acyloxy (g) C-i-C4 alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C-i-C4 alkyl) which may be substituted with 1-6 substituents selected from (a) Ci - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (b) halogen (c) (C1- C4 alkyl) halo, (d) C1-C4 alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetra- fluoropropyl and (m) tetrafluoropropoxyl;
B is selected from oxygen and sulphur atoms; and
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) C1-C4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl.
1. A method of treating or preventing fungal infection in an animal comprising administering to said animal a compound of Formula 111
Figure imgf000105_0001
FORMULA m
and its pharmaceutically acceptable salts, enantiomers, diastereomers, N- oxides, prodrugs or metabolites, wherein
R is selected from the group consisting of (1 ) C-1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (2) Cι-C4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C-j-C acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
R-i is selected from the group consisting of (1 ) hydrogen, (2) C1-C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) C1-C4 alkoxy;
R5 is selected from the group (1 ) hydrogen, (2) Ci- C alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C -C alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C-i-C alkoxy and amino (b) C-i-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) C1-C4 acyloxy (g) C1-C4 alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C1-C4 alkyl) which may be substituted with 1-6 substituents selected from (a) Ci - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino, (b) halogen (c) (Cr C4 alkyl) halo, (d) CrC4 alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetrafluoropropyl and (m) tetrafluoropropoxyl;
X is selected from the group consisting of CH2, CO, CS, SO2 and -N=N-; Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) CrC4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl; and
B is selected from oxygen and sulphur atoms.
12. A method of treating or preventing fungal infection in an animal comprising the step of administering to said animal the pharmaceutical composition according to claims 6 and 7.
13. A process for preparing a compound of Formula IA
Figure imgf000107_0001
FORMULA IA
wherein X is selected from the group consisting of CH2, CO, CS, SO2 and - N=N-;
R is selected from the group consisting of (1) Cι-C alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (2) C1-C4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C1-C4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
Ri and R2 are each independently selected from the group consisting of (1 ) hydrogen, (2) C1-C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) C C4 alkoxy;
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) C-i-C4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl;
R3 is selected from the group consisting of Cι-C alkyl group, halogen, hydroxy, Cι-C alkoxy, nitro, amino, cyano, carboxyl and SO2R' wherein R' is hydrogen, alkyl or aryl; and
Xi, X2, Yι, Y2 and Z are independently selected from the group consisting of halogen, nitro, cyano, amino, sulphonyl, aryl or substituted aryl, C C4 alkyl, Cι-C alkoxy, carboxyl or protected carboxyl;
which comprises reacting 1-[2-(2,4-disubstituted phenyl)-2,3-epoxy derivative of 1 ,2,4-triazole of Formula IV
Figure imgf000109_0001
FORMULA IV
wherein X, R and Ri are the same as defined above with triazol-3-one derivatives of Formula V
Figure imgf000109_0002
FORMULA V
wherein R2), R3, Xi, X2, Y, Y1, Y2 and Z have the same meanings as defined above, in the presence of sodium hydride to afford the desired compound of Formula IA.
14. A process for preparing a compound of Formula IA
Figure imgf000109_0003
FORMULA IA wherein X is selected from the group consisting of CH2, CO, CS, SO2 and - N=N-;
R is selected from the group consisting of (1 ) C1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (2) C1-C4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C1-C4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
R and R2 are each independently selected from the group consisting of (1 ) hydrogen, (2) C1-C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) Cι-C4 alkoxy;
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) C C4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl;
R3 is selected from the group consisting of C1-C4 alkyl group, halogen, hydroxy, C1-C4 alkoxy, nitro, amino, cyano, carboxyl and SO2R' wherein R' is hydrogen, alkyl or aryl; and Xi, X2, Y1, Y2 and Z are independently selected from the group consisting of halogen, nitro, cyano, amino, sulphonyl, aryl or substituted aryl, C1-C4 alkyl, C-t-C4 alkoxy, carboxyl or protected carboxyl;
which comprises reacting epoxide derivative of Formula VI
Figure imgf000111_0001
FORMULA VI
with 1 ,2,4-triazole to afford a compound of Formula IA.
15. A process for preparing a compound of Formula IB,
Figure imgf000111_0002
FORMULA IB
wherein X is selected from the group consisting of CH2, CO, CS, SO2 and -
N=N-;
R is selected from the group consisting of (1 ) Cι-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (2) Cι-C4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) Cι-C4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
Ri and R2 are each independently selected from the group consisting of (1 ) hydrogen, (2) C C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C-ι-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) C1-C4 alkoxy;
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) C1-C4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl;
R3 is selected from the group consisting of Cι-C4 alkyl group, halogen, hydroxy, C-i-C4 alkoxy, nitro, amino, cyano, carboxyl and SO2R' wherein R' is hydrogen, alkyl or aryl;
R is selected from the group consisting of hydrogen, C - C4 alkyl group which is unsubstituted or substituted;
B is selected from oxygen and sulphur atoms; and R5 is selected from the group (1 ) hydrogen, (2) C-]- C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C C4 alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C-1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (b) C1-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) C C4 acyloxy (g) C1-C4 alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C1-C4 alkyl) which may be substituted with 1-6 substituents selected from (a) Ci - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (b) halogen (c) (d- C4 alkyl) halo, (d) C1-C4 alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetrafluoropropyl and (m) tetrafluoropropoxyl, which comprises reacting a compound of Formula ID
Figure imgf000113_0001
FORMULA E) wherein X, R, R-i,R2, R3 and Y have the same meanings as defined above, with a compound of Formula R5 - N = C = B wherein R5 and B are the same as defined above to give a compound of Formula IC
Figure imgf000114_0001
FORMULA IC
which on reaction with R4Z, gives a compound of Formula IB wherein X, R, Ri, R2, R3, R4, R5Y and B have the same meanings as defined above and Z is any halogen atom.
16. A process for preparing a compound of Formula II
Figure imgf000114_0002
FORMULA π
wherein X is selected from the group consisting of CH2, CO, CS, SO2 and - N=N-;
R is selected from the group consisting of (1 ) C C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (2) C1-C4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C C4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
R-i is selected from the group consisting of (1 ) hydrogen, (2) Cι-C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C-]-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) Cι-C alkoxy;
R4 is selected from the group consisting of hydrogen, Ci - C4 alkyl group which is unsubstituted or substituted;
R5 is selected from the group (1 ) hydrogen, (2) C-i- C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C C4 alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C C-4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (b) C1-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) C1-C4 acyloxy (g) C1-C4 alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C-1-C4 alkyl) which may be substituted with 1-6 substituents selected from (a) d - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C C4 alkoxy and amino, (b) halogen (c) (Cr C4 alkyl) halo, (d) C C alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetra- fluoropropyl and (m) tetrafluoropropoxyl;
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) C1-C4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl; and,
B is selected from oxygen and sulphur atoms;
which comprises reacting a compound of Formula VII
Figure imgf000116_0001
FORMULA VII
with a compound R5-N=C=B, wherein R, R-i, R5, X and Y have the same meanings as defined above, to give a compound of Formula VIII
Figure imgf000117_0001
and which further comprises reacting the compound of Formula VIII with R Z, wherein R4 is selected from the group consisting of hydrogen, Ci - C alkyl group which is unsubstituted or substituted and Z is any halogen atom, to obtain a compound of Formula II.
17. A process for the preparation of a compound of Formula III
Figure imgf000117_0002
FORMULA m wherein
R is selected from the group consisting of (1) C1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (2) C1-C4 alkoxy, (3) halogen (4) formyl (5) carboxyl (6) C C4 acyloxy (7) phenyl or substituted phenyl (8) hydroxy (9) nitro (10) amino (11 ) furyl (12) triazolyl (13) thienyl (14) piperazinyl (15) morpholinyl (16) thiomorpholinyl (17) imidazolyl (18) oxazolyl and (19) triazolone-yl;
R-i is selected from the group consisting of (1 ) hydrogen, (2) C1-C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C-4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) C1-C4 alkoxy;
R5 is selected from the group (1 ) hydrogen, (2) C-i- C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C-1-C4 alkoxy and amino (b) C1-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) C1-C4 acyloxy (g) C1-C4 alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C-1-C4 alkyl) which may be substituted with 1-6 substituents selected from (a) Ci - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C-4 alkoxy and amino, (b) halogen (c) (C C4 alkyl) halo, (d) C1-C4 alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetrafluoropropyl and (m) tetrafluoropropoxyl,
X is selected from the group consisting of CH2, CO, CS, SO2 and -N=N-,
Y is a phenyl group which is unsubstituted or substituted with substituents each independently selected from the group consisting of (1 ) halogen (2) nitro (3) amino (4) cyano (5) carboxyl or protected carboxyl (6) hydroxy (7) C1-C4 alkoxy and (8) SO2R' wherein R' is hydrogen, alkyl or aryl; and,
B is selected from oxygen and sulphur atoms,
which comprises reacting a compound of Formula IX
Figure imgf000119_0001
FORMULA LX
with a compound of Formula B=C=N-R5, to give the desired compound of Formula III.
8. A process for preparing a compound of Formula IA wherein X=CH2, R=F,
Figure imgf000120_0001
(X=CH 2: R=F, R ,=H, Y=C 6H4-, R3=H)
and wherein
R2 is selected from the group consisting of (1 ) hydrogen, (2) C1-C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) C1-C4 alkoxy, and
Xi, X2, Y1, Y2 and Z are independently selected from the group consisting of halogen, nitro, cyano, amino, sulphonyl, aryl or substituted aryl, C-rC alkyl, C1-C4 alkoxy, carboxyl or protected carboxyl, which involves the reaction of triazol-3-one derivatives of Formula V wherein
Figure imgf000121_0001
FORMULA V (Ra = H, Y= C6H4-)
wherein R2, Xi, X2, 1 , Y2 and Z are the same as defined above, with the compound of Formula IV wherein R=F, Rι=H, X=CH2
Figure imgf000121_0002
FORMULA IV
in the presence of sodium hydride.
19. A process for the preparation of triazoI-3-one derivatives of Formula V wherein R3 =H, Y= C6 H4 -
Figure imgf000121_0003
FORMULA V
(R3 = H, Y = C6H -)
comprising reacting the substituted phenyl piperazine of Formula XIV
Figure imgf000122_0001
FORMULA XIV
wherein Xi, X2, Yi, Y2 and Z are independently selected from the group consisting of halogen, nitro, cyano, amino, sulphonyl, aryl or substituted1 aryl, Cι-C4 alkyl, CrC4 alkoxy, carboxyl or protected carboxyl, with 4- chloronitrobenzene to give the corresponding nitroaryl compound of Formula XV
Figure imgf000122_0002
FORMULA XV
which on catalytic reduction affords the anilino derivative of Formula XVI
Figure imgf000122_0003
FORMULA XVI
acylating the compound of Formula XVI with phenyl chloroformate to afford phenyl carbamate derivatives of Formula XVII
Figure imgf000123_0001
FORMULA XVπ reacting the carbamate derivative of Formula XVII, with hydrazine hydrate, forming semicarbazide derivative of Formula XVlll
Figure imgf000123_0002
Formula XVlll and cyclizing the compound of Formula XVlll with formamidine derivatives to form triazol-3-one derivatives of Formula V.
20. A process for preparing a compound of Formula IA wherein X=CH2, R=F, Rι=
CH3, Y=C6H4-, R3=H
Figure imgf000123_0003
(X=CH 2, R=F, R ι=H, Y=C 6H4-, R3=H) wherein R2 is selected from the group consisting of (1 ) hydrogen, (2) C-1-C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino (3) nitro (4) amino (5) cyano (6) carboxyl or protected carboxyl (7) SO2R' wherein R' is hydrogen, alkyl or aryl and (8) Cι-C4 alkoxy, and
Xi, X2, Y1, Y2 and Z are independently selected from the group consisting of halogen, nitro, cyano, amino, sulphonyl, aryl or substituted aryl, Cι-C4 alkyl, Cι-C4 alkoxy, carboxyl or protected carboxyl,
comprising reacting the 1 , 3-difluorobenzene of Formula X
Figure imgf000124_0001
FORMULA X
with racemic (+) 2-chloropropionyl chloride of Formula XIX
Figure imgf000124_0002
FORMULA XLX
o form a compound (±) 2-chloro-2-methyl-2', 4'-difluoroacetophenone of Formula XX
Figure imgf000125_0001
FORMULA XX
which on condensation with the intermediate of Formula V wherein R3=H, Y=C6H4- and R2, Xi, X2, Y1N2 and Z are as defined herein
Figure imgf000125_0002
FORMULA V
(R3 = H, Y= H4 )
in the presence of sodium hydride, forms the compound of Formula XXI
Figure imgf000125_0003
which is then epoxidized with trimethylsulphoxonium iodide (TMSI) in DMSO to give an epoxide derivative of Formula VI wherein X=CH2, R=F, Rι=CH3,
Figure imgf000125_0004
Figure imgf000126_0001
, R3=H)
which on condensation with 1 ,2,4-triazole forms the compound of Formula IA.
21. A process for preparing compounds of Formula II wherein X=CH2, R=F, Rι=H, Y=C-6H -
Figure imgf000126_0002
FORMULA π (X=CH2, R=F, R1=H, Y=C6H4-)
and wherein
R is selected from the group consisting of hydrogen, C-i - C4 alkyl group which is unsubstituted or substituted;
R5 is selected from the group (1) hydrogen, (2) Ci- C alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C-1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C C4 alkoxy and amino (b) C-ι-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) Cι-C acyloxy (g) Cι-C4 alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (Cι-C alkyl) which may be substituted with 1-6 substituents selected from (a) C - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C-i-C4 alkoxy and amino, (b) halogen (c) (C-i- C alkyl) halo, (d) Cι-C4 alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetra- fluoropropyl and (m) tetrafluoropropoxyl; and
B is selected from oxygen and sulphur atoms,
by reacting 2-(2,4-difluorophenyl)-3-(1 H-1 , 2,4-triazolyl)-1-[4-(piprazinyl) phenoxy]-propan-2-ol of Formula VII wherein X=CH2, R=F, Rι=H, Y=C6H4-
Figure imgf000127_0001
FORMULA VH (X=CH2; R=F, R]=H, Y=C6H4-) with the compound of Formula B=C=N-Rs, to form a compound of Formula VIII wherein X=CH2, R=F, R^H, Y=C6H4-
Figure imgf000128_0001
FORMULA Vm (X=CH2, R=F, R^H, Y^^ELf)
wherein R5 and B are as defined herein; and
further reacting the compound of Formula VIII with R4Z wherein R4 is selected from the group consisting of hydrogen, Ci - C alkyl group which is unsubstituted or substituted, in the presence of sodium hydride to give the required compound of Formula II.
22. A process for preparing a compound of Formula II wherein X=CH2, R=F, R-ι=CH3, R4 =H, Y=CeH4-
Figure imgf000128_0002
FORMULA π (X=CH2, R=F, R1=CH3, R4=H, Y=C6H4- )
wherein R5 is selected from the group (1 ) hydrogen, (2) Ci- C alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino (b) C1-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) C-1-C4 acyloxy (g) C1-C4 alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C1-C4 alkyl) which may be substituted with 1-6 substituents selected from (a) Ci - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (b) halogen (c) (C1- C alkyl) halo, (d) C1-C4 alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetrafluoropropyl and (m) tetrafluoropropoxyl, and
B is selected from oxygen and sulphur atom,
which comprises treatment of 2,4-diflϋoro-α-methyl-phenacyl chloride of
Formula XXII,
Figure imgf000130_0001
FORMULA XXπ with 1-acetyl-4-hydroxyphenylpiperazine of Formula XXIII,
Figure imgf000130_0002
FORMULA XXm
to form 2-[4-(4-acetylpiperazine)phenoxy]-2-methyl-2',4'-difluoroacetophen- one of Formula XXIV,
Figure imgf000130_0003
which on treatment with trimethyl sulphoxonium iodide forms the corresponding epoxide of Formula XXV,
Figure imgf000131_0001
FORMULA XXV
which is then reacted with 1 ,2,4-triazole to yield a compound of Formula XXVI,
Figure imgf000131_0002
which on hydrolysis gives a compound of Formula VII wherein X=CH2, R=F, R =CH3, Y=CeH4
Figure imgf000131_0003
FORMULA VH (X=CH2, R=F, ^=01,, Y=C6H4-) and reacting the compound of Formula VII with R5-N=C=B gives the compound of Formula II.
23. A process for preparing a compound of Formula III wherein X=CH2, R=F, Rι=H, Y=C6H4-
Figure imgf000132_0001
FORMULA m (X=CH2, R=F, R1=H, Y=C6H4 )
wherein
B is selected from oxygen and sulphur atoms, and
R5 is selected from the group (1 ) hydrogen, (2) Ci- C4 alkyl group which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C alkoxy and amino, (3) phenyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of (a) C1-C4 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, Cι-C4 alkoxy and amino (b) Cι-C4 alkoxy, (c) halogen, (d) formyl (e) carboxyl (f) Cι-C4 acyloxy (g) C1-C4 alkoxycarbonyl amino (h) phenyloxy or naphthyloxy carbonylamino (i) semicarbazido (j) formamido (k) thioformamido (I) hydroxy (m) nitro (n) amino (o) furyl (p) triazolyl (q) thienyl (r) oxazolyl (s) imidazolyl (t) CF2 and (u) OCF3 (4) naphthyl or naphthyl (C1-C4 alkyl) which may be substituted with 1-6 substituents selected from (a) C1 - C5 alkyl which is unsubstituted or substituted with 1-3 substituents each independently selected from the group consisting of halogen, hydroxy, C1-C4 alkoxy and amino, (b) halogen (c) (C-i- C alkyl) halo, (d) C-1-C4 alkoxy (e)hydroxy (f) amino (g) carboxyl (h) trifluoromethoxyl (i) trifluoromethyl (j) tetrafluoroethyl (k) tetrafluoroethoxyl (I) tetrafluoropropyl and (m) tetrafluoropropoxyl,
comprising reacting 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1 H-1 ,2,4-triazole of Formula IV wherein R=F, X=CH2, R- H
Figure imgf000133_0001
FORMULA IV (R=F, X=CH2, Rι=H) with N-methyl-4-nitroaniline of Formula XXVII gives 2-(2,4-difluorophenyl)-2- hydroxy-3-(1 H,1 ,2,4-triazol-1-yl)-1-propylamino-1 N, -methyl-4-nitrobenzene of Formula XXVIII
Figure imgf000133_0002
FORMULA XXVm which on reduction gives 2-(2,4-diflurophenyl)2-hydroxy-3-(1 H-1 ,2,4-triazoM - yl)-1-propylamino-1 H methyl 4-aniline of Formula IX wherein X=CH2, R=F,
Figure imgf000134_0001
FORMULA LX (X=CH2, R=F, R5=H, Y=C6H4")
which on reaction with B=C=N-R5 gives the compound of Formula III.
PCT/IB2001/000300 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections WO2001066551A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU34023/01A AU3402301A (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections
JP2001565367A JP2004501867A (en) 2000-03-07 2001-03-01 Azole compounds as therapeutics for fungal infections
EP01906061A EP1278755A2 (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections
CA002402345A CA2402345A1 (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections
NZ521241A NZ521241A (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections
PL01365072A PL365072A1 (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN198/DEL/2000 2000-03-07
IN198DE2000 IN191188B (en) 2000-03-07 2000-03-07
US09/575,578 US6670363B1 (en) 2000-03-07 2000-05-22 Azole compounds as therapeutic agents for fungal infections
US09/575,578 2000-05-22

Publications (3)

Publication Number Publication Date
WO2001066551A2 true WO2001066551A2 (en) 2001-09-13
WO2001066551A3 WO2001066551A3 (en) 2002-03-07
WO2001066551A8 WO2001066551A8 (en) 2003-06-26

Family

ID=26324879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000300 WO2001066551A2 (en) 2000-03-07 2001-03-01 Azole compounds as therapeutic agents for fungal infections

Country Status (8)

Country Link
EP (1) EP1278755A2 (en)
JP (1) JP2004501867A (en)
AU (1) AU3402301A (en)
CA (1) CA2402345A1 (en)
NZ (1) NZ521241A (en)
PL (1) PL365072A1 (en)
RU (1) RU2002126272A (en)
WO (1) WO2001066551A2 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044160A1 (en) * 2000-11-30 2002-06-06 Senju Pharmaceutical Co., Ltd. Pancreatitis remedies and medicines for prevention and therapy of reflux esophagitis
WO2003027103A1 (en) * 2001-09-25 2003-04-03 Ranbaxy Laboratories Limited Synthesis of key azole-antifungal intermediates
WO2004018485A1 (en) * 2002-08-26 2004-03-04 Ranbaxy Laboratories Limited Azole derivatives as antifungal agents
US6710049B2 (en) 2000-12-26 2004-03-23 Ranbaxy Laboratories Limited Azole compounds as anti-fungal agents
JP2006505576A (en) * 2002-10-24 2006-02-16 バイエル・クロツプサイエンス・エス・アー Antifungal agents containing arylamidine derivatives
WO2007020888A1 (en) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent, and therapeutic agent for sleep disorder
US7230023B2 (en) 2001-02-22 2007-06-12 Sankyo Company, Limited Water-soluble triazole fungicide
CN102617494A (en) * 2012-03-15 2012-08-01 南京工业大学 Triazole compounds containing olefine ether structure, and preparation method and application thereof
WO2012158844A1 (en) 2011-05-17 2012-11-22 Shionogi & Co., Ltd. Heterocyclic compounds
WO2012177986A2 (en) 2011-06-22 2012-12-27 Vyome Biosciences Conjugate-based antifungal and antibacterial prodrugs
WO2014195872A1 (en) 2013-06-04 2014-12-11 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
US9017722B2 (en) 2001-01-29 2015-04-28 Intermune, Inc. Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
WO2018060070A1 (en) 2016-09-29 2018-04-05 Bayer Cropscience Aktiengesellschaft Novel triazole derivatives
US10188637B2 (en) 2016-03-29 2019-01-29 Hoffmann-La Roche Inc. Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
EP3698793A1 (en) 2014-01-29 2020-08-26 Vyome Therapeutics Limited Besifloxacin for the treatment of resistant acne

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0567982A1 (en) * 1992-04-28 1993-11-03 Takeda Chemical Industries, Ltd. Azole compounds, their production and use
EP0659751A1 (en) * 1993-12-22 1995-06-28 Takeda Chemical Industries, Ltd. Optically active azole derivatives, their production and use
US5811426A (en) * 1994-07-12 1998-09-22 Janssen Pharmaceutica, N.V. Urea and thiourea derivatives of azolones
WO1999058529A1 (en) * 1998-05-14 1999-11-18 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0567982A1 (en) * 1992-04-28 1993-11-03 Takeda Chemical Industries, Ltd. Azole compounds, their production and use
EP0659751A1 (en) * 1993-12-22 1995-06-28 Takeda Chemical Industries, Ltd. Optically active azole derivatives, their production and use
US5811426A (en) * 1994-07-12 1998-09-22 Janssen Pharmaceutica, N.V. Urea and thiourea derivatives of azolones
WO1999058529A1 (en) * 1998-05-14 1999-11-18 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044160A1 (en) * 2000-11-30 2002-06-06 Senju Pharmaceutical Co., Ltd. Pancreatitis remedies and medicines for prevention and therapy of reflux esophagitis
US6710049B2 (en) 2000-12-26 2004-03-23 Ranbaxy Laboratories Limited Azole compounds as anti-fungal agents
US9561217B2 (en) 2001-01-29 2017-02-07 Intermune, Inc. Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
US9017722B2 (en) 2001-01-29 2015-04-28 Intermune, Inc. Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
US7230023B2 (en) 2001-02-22 2007-06-12 Sankyo Company, Limited Water-soluble triazole fungicide
WO2003027103A1 (en) * 2001-09-25 2003-04-03 Ranbaxy Laboratories Limited Synthesis of key azole-antifungal intermediates
EP1546158A1 (en) * 2002-08-26 2005-06-29 Ranbaxy Laboratories, Ltd. Azole derivatives as antifungal agents
WO2004018486A1 (en) * 2002-08-26 2004-03-04 Ranbaxy Laboratories Limited Azole derivatives as antifungal agents
WO2004018485A1 (en) * 2002-08-26 2004-03-04 Ranbaxy Laboratories Limited Azole derivatives as antifungal agents
JP2006505576A (en) * 2002-10-24 2006-02-16 バイエル・クロツプサイエンス・エス・アー Antifungal agents containing arylamidine derivatives
US7812025B2 (en) 2005-08-12 2010-10-12 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
WO2007020888A1 (en) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent, and therapeutic agent for sleep disorder
WO2012158844A1 (en) 2011-05-17 2012-11-22 Shionogi & Co., Ltd. Heterocyclic compounds
US9156830B2 (en) 2011-05-17 2015-10-13 Shionogi & Co., Ltd. Heterocyclic compounds
WO2012177986A2 (en) 2011-06-22 2012-12-27 Vyome Biosciences Conjugate-based antifungal and antibacterial prodrugs
CN102617494A (en) * 2012-03-15 2012-08-01 南京工业大学 Triazole compounds containing olefine ether structure, and preparation method and application thereof
CN102617494B (en) * 2012-03-15 2014-10-29 南京工业大学 Triazole compounds containing olefine ether structure, and preparation method and application thereof
WO2014195872A1 (en) 2013-06-04 2014-12-11 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
EP3698793A1 (en) 2014-01-29 2020-08-26 Vyome Therapeutics Limited Besifloxacin for the treatment of resistant acne
US10188637B2 (en) 2016-03-29 2019-01-29 Hoffmann-La Roche Inc. Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
WO2018060070A1 (en) 2016-09-29 2018-04-05 Bayer Cropscience Aktiengesellschaft Novel triazole derivatives

Also Published As

Publication number Publication date
PL365072A1 (en) 2004-12-27
RU2002126272A (en) 2004-08-10
WO2001066551A8 (en) 2003-06-26
JP2004501867A (en) 2004-01-22
CA2402345A1 (en) 2001-09-13
NZ521241A (en) 2004-02-27
EP1278755A2 (en) 2003-01-29
WO2001066551A3 (en) 2002-03-07
AU3402301A (en) 2001-09-17

Similar Documents

Publication Publication Date Title
EP1278755A2 (en) Azole compounds as therapeutic agents for fungal infections
HU211474A9 (en) Azole compounds, their production and use
US7189858B2 (en) N-phenyl substituted carbamoyloxyalkyl-azolium derivatives
US5545652A (en) Triazole and imidazole compounds and their use as antifungal therapeutic agents
KR100572996B1 (en) Antifungal azole compounds having fluorovinyl ether group as side chain and process for the preparing same
JPH1045750A (en) Azole compound, its production and use
SK16812000A3 (en) Water soluble azoles as broad-spectrum antifungals
US20060178415A1 (en) Azole derivatives as antifungal agents
US6670363B1 (en) Azole compounds as therapeutic agents for fungal infections
JP2965532B2 (en) N-benzyl azolium derivative
KR100509171B1 (en) Amino Acid Ester Containing Azole Antifungals
AU740324B2 (en) New triazoles as therapeutic agents for fungal infections
NZ530614A (en) Azole compounds as therapeutic agents for fungal infections
US6710049B2 (en) Azole compounds as anti-fungal agents
US6153616A (en) Triazoles as therapeutic agents for fungal infections
US20040242896A1 (en) Azole compounds as anti-fungal agents
MXPA04010066A (en) Derivatives of 2,2,4-trisubstituted tetrahydrofuran as antifungal agents.
JPH08104676A (en) Azole compound, its production and use
AU2002217365A1 (en) Azole compounds as anti-fungals agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2001 565367

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001906061

Country of ref document: EP

Ref document number: 2402345

Country of ref document: CA

Ref document number: 521241

Country of ref document: NZ

Ref document number: 34023/01

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2002 2002126272

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2001906061

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 37/2001 UNDER (71) THE ADDRESS OF "RANBAXY LABORATORIES LIMITED" CORRECTED; UNDER (72, 75) THE ADDRESSES OF "VERMA, ASHWANI, KUMAR", "ARORA, JASBIR, SINGH" AND "RATTAN, ASHOK" CORRECTED

WWP Wipo information: published in national office

Ref document number: 521241

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521241

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001906061

Country of ref document: EP